**Chapter number & Name (e.g. Ch-1…):**

**List of Authors (in order):**

Address, Title and Affiliation for each Author

Sample Author listing:

**Jane Smith, MD**

Chief of Oncology

Community Hospital

Anytown, USA)

**Chapter Editor:**

**Chapter data:**

Overview word count: 303 (< 300)

Total word count: Recommended word count:

Words (including 200 words/Figure 38-or table):

References: Recommended reference count:

Tables: (add 200 words/table)

Figures: (add 200 words/figure)

Supplementary tables:

Supplementary figures:

**Formatting checklist for submission**

**Face page** inserted as first page in full text document.

One-inch margins, left justified, Times New Roman 12 pt font

Headings should not be numbered (with roman numerals or letters)

Heading level numbers indicate hierarchy, but will not appear in the finished text. (ex. <1> Descriptive Epidemiology, <2> Geographic Patterns, <3> In U.S., <3> International, <2> Temporal Patterns etc.)

All text and references should be double-spaced

Page numbers & (total number of pages) at center bottom of page

Indicate placement of table/Figure 38-**after** the paragraph they are first mentioned.   
“[Insert Table 38-3-1 here]”

**Formatting below - for Final submission** (**to OUP)**

**Sections:**

Overview:

Extended abstract < 300 words describing highlights of chapter

No in-text citations, tables, figures etc.

Tables/figures:

Numbering style [3-1] means first figure/Table 38-in chapter 3.

Tables formatted cleanly (minimize lines between columns and rows)

Figures should be clearly legible in black and white as well as color. Lines should be labeled with patterns (as well as color where desired).

References

Check that recommended style was used (output style for endnote v 20151001)   
*(If your in-text citation does not contain a period after et al (Smith et al., 2011) you should try to re-upload the style from the portal)*

All references in text, tables and figures should be included in and cited from the reference list

**FINAL submission (to OUP) should be a clean copy**

No track changes or comments

No Line numbers

**Documents to be uploaded:**

**Full text** (including face page, overview, body of text and references – no figures or tables, no Figure 38-legends)

**Figures** in one document with legends and in order of appearance

**Tables** in one document with legends and in order of appearance

**Other** - **Listing of** **all figures and tables** used and whether they need copy right permissions. All copyright permissions will be obtained by OUP (NEW).

**More information:** [Portal: guidance documents](https://portals.dceg.cancer.gov/4thedition/guidance-documents)

**Ch# & Name of Chapter: Ch 38 Leukemias**

**List of Authors (in order) :** Martha S. Linet, M.D. ; Lindsay M. Morton, Ph.D.; Susan S. Devesa, Ph.D.; Graça M. Dores, M.D.

**Chapter data:**

Overview word count: 303 (< 300)

Total word count: 19,932 Recommended word count: : 21,945

Words (including 200 words/Figure 38-or table): 20,932

References: 318 Recommended reference count: 300

Tables: 1 (add 200 words/table)

Figures: 4 (add 200 words/figure)

Supplementary tables: 0

Supplementary figures:0

**Formatting checklist for FINAL submission**

ok This **Face page** inserted as first page in full text document.

ok One-inch margins &12 pt Times New Roman font

ok Headings level numbers indicated   
( <1> Main header , <2> sub-header etc.)

? Table/Figure 38-placement indicators inserted (e.g. “[Insert Table 38-3.1 here]”

Tables formatted cleanly with as few internal lines as possible

Figures should be clearly legible in black and white (for the print version of the book). Use of patterned lines is preferred to different colors if more than 4 lines in a line graph

ok All text and references double-spaced

ok Page numbers (total number of pages) at center bottom of page

NO Line numbers

NO track changes

**Documents to be uploaded:**

**Full text** (including face page, body of text and references – no figures or tables, no Figure 38-legends)

**Figures** and supplementary figures each in one separate document with legends and in order of appearance

**Tables** and supplementary tables each in one separate document with legends and in order of appearance

**Other** - **Listing of** **all figures and tables** used and whether they need copy right permissions. All copyright permissions are to be obtained by authors and posted to the portal no later than May 31st (find more information in the [OUP handbook](http://fdslive.oup.com/www.oup.com/academic/pdf/authors/AuthorsHandbook_Sept2015.pd)).

**More information:**

1. [Portal: guidance documents](https://portals.dceg.cancer.gov/4thedition/guidance-documents)
2. [OUP author handbook](http://fdslive.oup.com/www.oup.com/academic/pdf/authors/AuthorsHandbook_Sept2015.pdf) (we are not expected to follow all requirements in this handbook

**List of Authors:**

Martha S. Linet, M.D.

Division of Cancer Epidemiology and Genetics

National Cancer Institute

9609 Medical Center Drive, Room 7E452

Rockville, Maryland 20850-9778 USA

Lindsay M. Morton, Ph.D.

Division of Cancer Epidemiology and Genetics

National Cancer Institute

9609 Medical Center Drive

Rockville, Maryland 20850-9778 USA

Susan S. Devesa, Ph.D.

Division of Cancer Epidemiology and Genetics

National Cancer Institute

9609 Medical Center Drive, Room 7E452

Rockville, Maryland 20850-9778 USA

Graça M. Dores, M.D.

Division of Cancer Epidemiology and Genetics

National Cancer Institute

9609 Medical Center Drive, Room 7E452

Rockville, Maryland 20850-9778 USA

Maximum page length: 22.5

Words: 20,932 (includes 1,000 for 4 figures and 1 table) Maximum word length: 21,945

References: 313 Maximum references: 300

Leukemia chapter in 3rd edition: = 18,761 words or 14.2 pages

References can include up to 408 (8 pages) if keep word total <18,761

**<1> OVERVIEW (word count is 303)**

The 2001 World Health Organization (WHO) classification of hematopoietic and lymphoid neoplasms categorized “the leukemias” into two major groupings – myeloid and lymphoid neoplasms. **Myeloid neoplasms,** which are the primary focus of this chapter, include acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). **Lymphoid neoplasms** are mostly reviewed as part of non-Hodgkin lymphoma in Chapter 40, although descriptive patterns and selected etiologic studies are briefly discussed in this chapter because of historical trends.

Worldwide, leukemias are ranked 11th among all cancer types, comprising approximately 2.5 percent of all malignancies. For most leukemias, rates are higher in males than females, and age-adjusted incidence rates show more limited international variation than most solid tumors, ranging from , ~3-fold for acute lymphocytic leukemia (ALL),4-fold for chronic myeloid leukemia (CML), , 10-fold for AML to 40-fold for chronic lymphocytic leukemia (CLL).

Exposure to ionizing radiation and certain chemical carcinogens (e.g., cytotoxic chemotherapy, benzene, formaldehyde) are the most consistently associated risk factors for MDS and/or AML (MDS/AML). Radiation also has been linked with CML, and cigarette smoking with AML. Fewer risk factors have been identified for MPNs. Some evidence implicates increased risks of AML in rubber workers, farmers, and other agricultural workers. Several studies have reported increased risks of multiple myeloid neoplasms in patients with autoimmune diseases and in recipients of solid organ transplants. In addition, most myeloid neoplasms, with the possible exception of CML, demonstrate familial aggregation.

Since established risk factors do not explain most of the occurrence of myeloid neoplasms, opportunities for prevention are currently limited, but would include reduction in exposure to radiation; limiting occupational and general population exposure to benzene, formaldehyde and other chemicals; and cessation of and avoidance of smoking. Improvements in classification, ascertainment, diagnosis, and molecular characterization of myeloid neoplasms are critical to clarify etiology and to develop measures for prevention and effective treatment.

**<1> INTRODUCTION**

Most, if not all, acute and chronic leukemias appear to develop from a preleukemic state that progresses to overt leukemia over time (Shlush and Minden, 2015). Included among the preleukemic entities are myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), “overlap” disorders termed myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and monoclonal B-cell lymphocytosis. All of these entities are clonal stem cell disorders that can progress or transform into leukemia. Understanding the epidemiology of the leukemias and the preleukemic states has been complicated by changing classification schemes and by the fact that many preleukemic entities have not always been reporTable 38-to cancer registries, thereby often being excluded from population-based cancer statistics.

Worldwide in 2012, leukemias were ranked 11th among all cancer types, comprising approximately 2.5 percent of all malignancies and an estimated 352,000 incident cases (Ferlay et al., 2014). In the U.S., an estimated 60,140 cases will be diagnosed in 2016 (including 19,950 acute myeloid leukemia (AML), 8,220 chronic myeloid leukemia (CML), 6,590 acute lymphocytic leukemia (ALL), 18,960 chronic lymphocytic leukemia (CLL), and 6,420 other leukemias), and the number of deaths from leukemia is estimated as 24,400 (including 10,430 AML, 1,070 CML, 1,430 ALL, 4,660 CLL, and 6,810 other leukemias) (Siegel et al., 2016). Leukemias are estimated to comprise 4% and 3% of all incident cancers among U.S. males and females, respectively, and 4% of all cancer deaths in both males and females (Siegel et al., 2016).

In the U.S., all MDS and MPN became reporTable 38-to the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program in 2001. In 2012, 3,981 and 3,291 cases of MDS and MPN, respectively, were diagnosed in 18 cancer registry areas representing 26% of the U.S. population, including 2,304 and 1,677 cases of MDS and 1,672 and 1,619 cases MPN among males and females, respectively (SEER-18). In contrast, based on data from 64 European cancer registries (1995-2002), 7,460 cases of MDS and 15,269 cases of MPN were estimated to occur annually (Visser et al., 2012). Mortality data on MDS and MPN are sparse. In 2009 there were 6,007 deaths in the U.S. with an underlying cause of death specified as MDS (Polednak, 2013), and in 2006, 3,303 deaths were attributed to MPN (Polednak, 2011).

The unifying feature of the leukemias is that they arise from an accumulation of multiple, stepwise genetic and epigenetic changes in the hematopoietic stem cell (HSC) and committed progenitors. A preleukemic cell contains only a subset of the genetic and epigenetic changes characterizing leukemic cells (Shlush and Minden, 2015). In the normal state, HSCs differentiate into progenitor cells that give rise to myeloid and lymphoid progenitor cells and eventually all mature blood elements (Hoffman et al., 2013; Shizuru et al., 2005). Throughout this highly regulated, hierarchical differentiation and maturation process, lymphoid and myeloid cells acquire distinct phenotypes. Genetic mutations involving primitive stem cells or early myeloid-committed progenitors result in clonal proliferation and accumulation of immature hematopoietic cells (e.g., blasts) of myeloid lineage (e.g., AML) in the bone marrow, peripheral blood or other tissues (Swerdlow et al., 2008; Kipps and Huan-You, 2015). When the affected pluripotent stem cell results in maturation arrest of more mature myeloid cells and ensuing accumulation of these more differentiated phenotypes, chronic leukemias then ensue. In CML the affected pluripotent stem cell is consistently associated with a *BCR-ABL1* fusion gene located on the Philadelphia chromosome, resulting in the accumulation of more mature myeloid cells of erythroid, granulocytic, monocytic, dendritic, and megakaryocytic lineages (Lichtman, 2015). For many of the lymphoid neoplasms, the “cell of origin” represents the stage of differentiation of the tumor cells rather than the cell in which the initial transforming event occurred (Jaffe et al 2001). Genetic mutations involving B-cell progenitors may result in the accumulation of phenotypically immature-appearing lymphoid cells (blasts), as seen in ALL, or mature-appearing lymphocytes, as in CLL. The MDS are a heterogeneous group of clonal HSC neoplasms characterized by dysplasia (disordered maturation) in one or more cell lines and ineffective hematopoiesis that may result in peripheral cytopenias of one or more cell lines (Swerdlow et al., 2008). In contrast, the MPN are clonal HSC neoplasms associated with proliferation of one or more of the myeloid lineages and absence of dysplasia. The MDS/MPN include both dysplastic and proliferative features.

**<1> HEMATOPOIETIC AND LYMPHOID CLASSIFICATION SCHEMES**

**<2> EVOLUTION OF CLASSIFICATION**

Earlier reviews provided a comprehensive summary of the history of leukemia classification (Linet S&F chapter 2006). The landmark French-American-British (FAB) classification (Bennett et al., 1976, 1989, 1994, 2013) achieved international consensus on morphologic criteria. Subsequent efforts to incorporate developmental and functional aspects of hematopoiesis according to lineage as well as key aspects of pathogenesis and cytogenetic and immunophenotypic characteristics (McKenna, 2000; Bennett, 2000) culminated in the 2001 WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue (Jaffe et al., 2001). This classification included genetic data that were more predictive of disease behavior and outcome than morphology and also added new disease categories. Cytogenetic alterations have long been identified as hallmarks of many cases of hematopoietic and lymphoid tumors, but the advent of and dramatic technical developments in high-resolution profiling led to notable advances in clarifying the genetic basis of these disorders. Certain markers have been identified as clinically meaningful therapeutic targets or as helpful prognostic markers (Inaba et al., 2013; Bochtler et al., 2015). With this rapid evolution and emergence of new information, the WHO classification was updated in 2008 (Swerdlow et al., 2008). The 2008 WHO classification considered lineage-specific disease categories (myeloid, lymphoid, and histiocytic/dendritic cell), distinguished immature neoplasms (e.g., AML, lymphoblastic leukemia/lymphoma) from more mature neoplasms (*e.g*., MDS, MPN, MDS/MPN), introduced new disease-defining criteria, and identified new disease entities. Multidisciplinary experts in international working groups (such as the International Working Group for Myelofibrosis Research and Treatment, the European Group for the Immunologic Classification of Leukemia, and the National Cancer Institute-sponsored Working Group on CLL) continue to meet and provide recommendations to ensure that the classification and updates will be clinically useful.

The 2001 WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue categorized the lymphoid neoplasms into 3 broad categories: B-cell neoplasms, T- and NK-cell neoplasms, and Hodgkin lymphoma. Within the former 2 categories, the leukemias were classified with the lymphomas due to several of these entities having circulating (blood) and solid (tissue) phases that represent different manifestations of the same disease (e.g., CLL (blood phase) and small lymphocytic lymphoma (tissue phase), lymphoblastic leukemia (blood phase) and lymphoblastic lymphoma (tissue phase)) (Jaffe et al., 2001). Therefore, to be consistent with the WHO classification, this “leukemia” review will focus on the characteristics, descriptive epidemiology, and known and suspected risk factors of the myeloid neoplasms occurring in adults. Detailed findings from more recent epidemiologic studies of ALL and CLL will be found in Chapter 40 on non-Hodgkin lymphoma, and the epidemiology of myeloid neoplasms of childhood will be found in Chapter 59 on childhood cancers. However, because earlier descriptions of leukemia incidence and mortality often focused on all forms of leukemia combined (e.g., AML, CML, ALL, CLL; hereafter designated total leukemia) and most epidemiologic studies prior to the last decade or so considered lymphoid leukemias in conjunction with myeloid leukemias, some material on lymphoid leukemias is included below in the sections on descriptive and analytical epidemiologic studies and in Chapter 40 in this book.

The International Classification of Diseases (ICD) for Oncology (ICD-O) classification, primarily used for coding tumor morphology and topography in cancer registries, has similarly evolved over time, and the 2001 WHO classification incorporated codes from the third edition of ICD-O (ICD-O-3) (Fritz et al., 2000). The 2008 WHO classification included ICD-O-3 morphology codes and also proposed provisional codes for the forthcoming edition of ICD-O-4 that remain subject to change. The complex, continuing evolution of the international classification of hematopoietic and lymphoid neoplasms has led some population-based cancer registries to develop special measures to improve our understanding and interpretation of information in pathology and clinical records and thereby allow more accurate coding of these neoplasms (Ruhl et al., 2015).

**<1> MYELOID NEOPLASMS AND THE WHO CLASSIFICATION**

In the WHO classification the term “myeloid” includes all cells that belong to granulocytic (neutrophil, eosinophil, basophil), monocytic/macrophage, erythroid, megakaryocytic and mast cell lineages (Vardiman et al., 2009). Utilizing the WHO criteria, the diagnoses of myeloid neoplasms utilize morphologic, cytochemical, immunophenotypic, and cytogenetic characteristics to determine the lineage and maturation of the neoplastic cells obtained from peripheral blood and bone marrow upon initial clinical presentation, prior to initiation of treatment.

**<2> WORLD HEALTH ORGANIZATION 2001 CLASSIFICATION**

**<3> Acute myeloid leukemia and related precursor neoplasms**

The 2001 WHO classification of myeloid neoplasms categorized AML arising *de novo* separately from AML evolving from antecedent MDS or MDS/MPN to better reflect the postulated distinct underlying leukemogenic mechanisms and prognoses (Jaffe et al., 2001). Whereas the latter (AML with multilineage dysplasia) is often associated with unfavorable cytogenetics, poor response to treatment, unfavorable prognosis, and genetic insults occurring over a lifetime (reflected by the increasing incidence with age), *de novo* AML typically is not associated with multilineage dysplasia, has a constant incidence throughout life, and is often associated with more favorable cytogenetic abnormalities, response to treatment, and prognosis. To better reflect the distinct clinical and biologic features of AML than the preceding morphology-based FAB classification, the 2001 WHO classification considered four major disease subgroups: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) AML and MDS, therapy-related; and 4) AML, not otherwise specified (NOS). Other significant changes in the 2001 WHO classification included a decrease in the blast percentage in the bone marrow or blood required to establish a diagnosis of AML from 30% to 20%. Furthermore, the presence of recurrent genetic abnormalities (t(8;21)(q22;q22), t(15;17)(q22;q12), and inv(16) (p13q22) or t(16;16)(p13;qi22)) was deemed diagnostic of AML irrespective of the percentage of blasts (Vardiman et al., 2002; Jaffe et al., 2001).

The subsequent 2008 WHO classification added three new entities within the category of AML with recurrent genetic abnormalities (AML with t(6;9)(p23;q34); AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); AML (megakaryoblastic) with t(1;22)(p13;q13)) and two provisional entities (AML with mutated *NPM1* and AML with *CEBPA*) (Swerdlow et al., 2008, Vardiman et al., 2009). Additional diagnostic refinements were further specified for acute promyelocytic leukemia with t(15; 17)(q22; q12) and AML with 11q23 (MLL). Other changes included renaming AML with multilineage dysplasia to AML with myelodysplasia-related changes to include AML cases with an antecedent MDS or MPN/MDS, myelodysplasia-related cytogenetic abnormality, or with 50% or more dysplastic changes in two or myeloid cell lines. The therapy-related MDS/AML category was renamed to therapy-related myeloid neoplasms (t-MDS/AML) and eliminated the subcategories of alkylating agent/radiation-related and topoisomerase II inhibitor-related AML. Two additional new AML categories were added: 1) myeloid proliferations related to Down syndrome to include Down syndrome-related transient abnormal myelopoiesis, MDS, and AML and 2) blastic plasmacytic dendritic cell neoplasms. The complete list of AML and related myeloid precursors included in the 2008 WHO classification with an associated ICD-O-3 code are specified in Table 38-1.

[insert Table 38-1 here]

**<3> Myelodysplastic syndromes**

In 1982, the FAB classification considered 5 entities within the category of MDS (previously also referred to as “pre-leukemia”), with the specified categories based on percent of blasts in the peripheral blood/bone marrow and other morphologic features. The MDS entities included in the FAB classification are specified in Table 38-2 with associated diagnostic bone marrow blast percentages.

[Insert Table 38-2 here]

With the new 20% blast threshold for diagnosis of AML introduced in the 2001 WHO classification, “refractory anemia with blasts in transformation” became an obsolete term. The 2001 WHO classification also refined the diagnostic criteria for refractory anemia and refractory anemia with ringed sideroblasts, introduced two new MDS categories (refractory cytopenia with multilineage dysplasia and MDS associated with isolated deletion of 5q), and defined two subtypes of refractory anemia with excess blasts (RAEB) – RAEB-1 and RAEB-2 – which are largely differentiated by percentage of blasts and absence or presence of Auer rods. Lastly, resulting from the debate as to whether CMML represents a myelodysplastic or myeloproliferative neoplasm (it has clinical and pathologic features of both), CMML was moved to a new disease group – MDS/MPN.

The 2008 WHO classification introduced additional changes to the diagnosis and classification of MDS, including a new broad category of refractory cytopenia with unilineage dysplasia. A new provisional category of refractory cytopenia of childhood also was proposed due to differences in clinical and pathologic features of MDS occurring among children and adults. In sum, the 2008 WHO classification scheme includes seven broad disease categories of MDS (Table 38-3).

[Insert Table 38-3 here]

With the WHO classifications outpacing the update of the ICD-O, some MDS entities are currently associated with a proposed ICD-O code. From an epidemiologic standpoint, it is important to recognize the evolution of diagnostic criteria that has ensued since the FAB classification, both within and between entities, and that the diagnostic criteria for an entity with an assigned ICD-O-3 code today may not reflect the same diagnostic criteria for that entity with an ICD-O-3 code assigned in the past. The same caveat should be considered when ICD-O-4 codes are introduced and applied to cases diagnosed in the past.

**<3> Therapy-related MDS/AML (t-MDS/AML)**

t-MDS/AML, a new entity included in the 2001 WHO classification that includes t-MDS and t-AML, is a rare but often fatal complication of cytotoxic treatments for malignant and non-malignant diseases. Like other MDS/AML, t-MDS/AML occurs as a consequence of acquired genetic alterations in the hematopoietic stem cell and progenitor cell involving multiple pathways. In comparison with *de novo* MDS/AML, however, t-MDS/AML has a higher rate of clonal abnormalities including -5, -7, 7q-, 13q-, del 17p, and -18. Cytogenetic assessment is important since favorable, intermediate, and unfavorable karyotypes have been related to prognosis, and the frequency of unfavorable karyotype is considerably higher in t-MDL/AML than in *de novo* MDS/AML (Godley and Larson 2008). Patients with t-MDS/AML have worse prognosis than those with *de novo* MDS/AML, even when they have the same chromosomal abnormalities. This suggests that there are biologic differences between t-MDS/AML and *de novo* MDS/AML that are not solely related to the specific chromosomal abnormalities (Granfeldt Ostgard et al., 2015). These differences are more evident for t-MDS/AML subsequent to cytotoxic chemotherapy or combined modality therapy, whereas some evidence suggests that t-MDS/AML occurring among patients who receive radiotherapy alone is more likely to share genetic features and clinical behavior with *de novo* MDS/AML (Nardi et al., 2012).

**<3> Myeloproliferative neoplasms**

The term “myeloproliferative disorders” was initially introduced in 1951 (Dameshek, 1951) and encompassed four disease entities that shared clinical and pathologic features: CML, polycythemia vera, essential thrombocythemia, and primary myelofibrosis. These chronic myeloproliferative disorders were further defined according to clinical and morphologic criteria by the Polycythemia Vera Study Group (PVSG) (PVSG, 1995). One major change associated with the 2001 WHO classification was that the diagnosis of CML could be “unequivocally” confirmed based on the presence of an associated genetic abnormality – the Philadelphia chromosome or *BCR/ABL1* fusion gene. Two additional disease entities were incorporated into the category of myeloproliferative disorders: chronic neutrophilic leukemia and chronic eosinophilic leukemia, including hypereosinophilic syndrome. In 2005, the discovery of the *JAK2 V617F* mutation substantially facilitated the diagnosis of the myeloproliferative disorders (James et al., 2005; Kralovics et al., 2005). Janus kinase 2 (JAK2) is a cytoplasmic tyrosine kinase that is integral for signaling by the receptors for erythropoietin, thrombopoietin, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and interleukin-3 (Campbell and Green, 2006). An acquired point mutation in *JAK2* leads to pathologic proliferation of myeloid precursors, and while it can be found in several MPN, MDS/MPN, and other myeloid neoplasms, it is found in more than 95% of cases of polycythemia vera and 50-60% of cases of essential thrombocythemia and primary myelofibrosis (Tefferi and Pardanani, 2015). The 2008 WHO classification incorporated information on *JAK2 V617F* mutations, as well as other activating mutations (e.g., *CALR*, *MPL*) into the diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Additional changes in the 2008 WHO classification included lowering the diagnostic platelet count threshold for essential thrombocythemia from >600 x 109/L to >450 x 109/L. Furthermore, the term “chronic myeloproliferative disorders” was changed to “MPN” to reflect the malignant nature of these clonal diseases, and systemic mastocytosis, which was considered as a separate disease category in the 2001 WHO classification, was incorporated into the MPN category. The specific MPN entities and their respective ICD-O-3 codes are included in Table 38-1.

**<3> Myelodysplastic/myeloproliferative neoplasms**

The category of MDS/MPN diseases was newly introduced with the 2001 WHO classification to include entities associated with both dysplastic and proliferative features, although either may predominate to different degrees (Jaffe et al., 2001). Along with CMML, which as noted above was previously included with MDS, this disease category also included atypical CML (lacks the Philadelphia chromosome); juvenile myelomonocytic leukemia (lacks the Philadelphia chromosome); and MDS/MPN disease, unclassifiable. In the 2008 WHO classification, atypical CML was renamed *BCR-ABL1*-negative CML to emphasize that it is a distinct entity from *BCR-ABL1*-positive CML (Swerdlow et al., 2008). Some cases of CMML with eosinophilia were reclassified to the new disease category of “myeloid and lymphoid neoplasms with eosinophilia and abnormalities of *PDGFRA*, *PDGFRB*, or *FGFR1*,” and refractory anemia with ringed sideroblasts associated with marked thrombocytosis was introduced as a provisional entity. While each of these entities is associated with an ICD-O-3 morphology code, some codes are shared with other disease entities (as specified in Table 38-4), an important consideration in epidemiologic studies.

[Table 38-4 here]

**<1> CLINICAL PRESENTATION**

There is notable variation in severity of disease and patient survival, both within a given myeloid leukemia and preleukemia subtype and between subtypes (Kadia et al., 2015; Ferrara and Schiffer, 2013; Dohner et al., 2015; Dores et al., 2012; Srour et al., 2016; Ades et al., 2014; Tefferri and Pardanani, 2015). Patients with AML often present with complications related to cytopenias involving one or more cell lines (anemia, leukopenia, thrombocytopenia), with a smaller proportion of patients presenting with complications of extreme leukocytosis. Generalized fatigue and weakness are common and often attributed to anemia. Bleeding, bruising, and petechiae are manifestations of thrombocytopenia and/or disseminated intravascular coagulation. Fever is most often related to underlying infection related to neutropenia (which increases risk of infection), although a minority of individuals may have fever related to the leukemia itself. Lymphadenopathy and hepatosplenomegaly are uncommon. Individuals with MDS also typically present with cytopenias involving one or more cell lines, but in contrast to AML, many are asymptomatic at presentation. Similar to AML, lymphadenopathy and hepatosplenomegaly are uncommon. In contrast, individuals with MPN generally present with elevations in one or more cell lines (erythrocytosis, leukocytosis, thrombocytosis), and splenomegaly (with or without hepatomegaly) is common. Individuals may be asymptomatic at presentation, with the diagnosis suspected based on complete blood count abnormalities, or may be found to have hepatosplenomegaly, thrombosis/bleeding episodes, common complications of MPN, or other manifestations of a hyperproliferative state.

**<1> TUMOR PROGRESSION MODELS (AML)**

Genomic and molecular data support that AML is a heterogeneous disease comprised of multiple distinct entities. Genetic changes resulting in distinct functional effects on hematopoietic precursors has led to the concept of leukemogenesis as a multi-step process that eventually leads to malignant transformation (Meyer and Levine, 2014). Whole genome sequencing in a study of 200 cases of de novo AML in The Cancer Genome Atlas Project found that among adult cancers, AML had the fewest number of mutations (CA Genome Atlas Research Network, 2013). On average, 13 coding mutations were identified per case, and of these, an average of 5 genes were recurrently mutated, suggesting a role for certain driver mutations resulting in leukemic transformation (Cancer Genome Atlas Research Network, 2013; Meyer and Levine, 2014; Kadia et al., 2015). At least one potential driver mutation was identified in each case of AML, confirming the recurrent nature of other passenger mutations that accumulate during leukemogenesis but do not have transforming capability (Meyer and Levine, 2014). The most commonly mutated genes (>5% frequency; e.g., *NPM1*, *FLT3*, *DNMT3a*, *IDH1,* *IDH2*, *TET2*, *RUNX1*, *TP53*, *CEBPA*, *NRAS*, *WT1*) were organized into functionally related categories hypothesized to be of biologic importance: 1) myeloid transcription-factor fusions/mutations, 2) *NPM1* mutations 3) tumor suppressor gene mutations, 4) epigenome-modifying gene mutations, 5) activated signaling pathway gene mutations, 6) cohesion-complex gene mutations, and 7) sliceosome-complex gene mutations (Kadia et al., 2015). Frequently occurring chromosomal abnormalities included t(15; 17), t(8;21), inv(16), abn11q23, monosomy 5 and monsomy 7 (Meyer and Levine, 2014). The role and prognostic implication of many of these genetic alterations remain under study.

**<1> DESCRIPTIVE EPIDEMIOLOGY**

**<2> INTERNATIONAL COMPARISONS**

Internationally, there has been non-uniform implementation of the WHO 2001 and 2008 classifications of hematopoietic and lymphoid neoplasms. Lack of availability of detailed clinicopathologic and molecular characterization in some countries has resulted in use of ICD-10 rather than ICD-O-3 in cancer registration, even in the most recent volume of Cancer Incidence in Five Continents (Volume X). Comparisons of leukemia data across many countries and populations for the most recent period (2003-2007) are therefore restricted to broad, older categories of the leukemias (AML, CML, ALL, CLL). International comparisons described below are based on cancer registries with fewer than 10% of leukemia cases reported as “unspecified type”.

**<3> International patterns in incidence of broad categories of leukemias by subtype**

Among adults ages 20-79 years diagnosed during 2003-2007, AML rates ranged from highs of 4.7 among males and 5.0 among females in Manila to lows of 1.9 and 1.5 in Costa Rica (high/low rate ratios of 2.5 and 3.3 among males and females, respectively) (Figure 38-1). AML incidence rates were highest and generally similar across North, Central, and South America; Europe; Oceania; and parts of Asia, while lowest in Africa and parts of Eastern Europe and East Asia. With rare exception (Mumbai, India and Manila, Philippines), incidence of AML was higher among males than females, with 40% or higher rates among males in Murcia, Spain; Hong Kong, China; Osaka, Japan; and New South Wales, Australia. CML rates varied about four-fold from 2.9 in France to 0.7 in Bangkok among males and from 1.5 in Cali and Belgium to 0.4 in Osaka and Bangkok among females, with slightly higher rates in Oceania, North America, and western Europe. The male-to-female incidence rate ratio for CML was <1.00 only in Quito, Ecuador and Gharbiah, Egypt, and exceeded 2.00 in Loire Atlantique, France; Hong Kong, China; and Osaka Prefecture, Japan. ALL generally was the least frequent adult leukemia type, and rates were notably highest in Central and South America and among U.S. Hispanic Whites in the SEER Program and otherwise similar across other geographic areas. While there was a tendency for male predominance in ALL, the rate ratio was <1.00 in seven registries. CLL incidence rates varied the most, with the highest rates in New Zealand of 8.1 (males) and 4.2 (females), 40 times the lowest rates in Osaka of 0.2 (males) and 0.1 (females); rates were also high in Canada and U.S. whites in North America; western, northern, and eastern Europe; and New South Wales, and low in east Asia. Worldwide, CLL incidence rates were higher among males than females everywhere except in Manila.

[Figure 38-1 here]

**<3> International patterns in temporal trends incidence of leukemia by subtype**

Comparison of temporal trends between studies is limited by calendar years included, given the potential influence of changing classification schemes over time. In the U.S., incidence of AML has remained sTable 38-among whites and blacks >20 year of age across four decades, 1973-2012 (Figure 38-2). In contrast, CML rates have been declining during the last two decades across all racial/ethnic groups, including Hispanic whites and Asians/Pacific Islanders. ALL incidence rose during the 1970s-80s, but rates generally stabilized thereafter among whites and blacks. CLL rates have remained sTable 38-among whites, but rates have slowly decreased since the 1970s among blacks. Among Hispanic whites and Asians/Pacific Islanders, CLL rates have not changed greatly during the limited timeframe for which racial/ethnic-specific incidence data have been available. In Denmark, incidence of AML, CLL, and to a lesser extent, ALL increased during 1943-2003, whereas CML decreased (Thygesen et al., 2009). During 1984-1993, AML, MPN (including CML) incidence rates decreased in the United Kingdom (U.K.), whereas ALL remained stable, and MDS rates increased (McNally et al., 1999). During 1991-2005, AML incidence rates increased in Western Australia (Gangatharan et al., 2013). More recently, several large studies have described incidence rates utilizing the WHO classification scheme (Sant et al., 2010, Smith et al., 2009, Smith 2011, Dores et al., 2012), however, longer follow-up will be needed to assess temporal trends subsequent to 2001.

[Figure 38-2 here]

**<2> DESCRIPTIVE PATTERNS OF MYELOID NEOPLASMS BY WHO SUBTYPE**

Some population-based cancer registries have implemented reporting of myeloid neoplasms using the WHO 2001 classification of hematopoietic and lymphoid neoplasms. The U.S. SEER population-based registries have trained registry staff to code these neoplasms using ICD-O-3 which has incorporated the WHO 2001 classification. Described below are descriptive patterns for myeloid neoplasms diagnosed in the U.S. among persons ages >20 for the period 2001-2012. Consistent with the clinical and molecular heterogeneity described among individuals with AML, incidence rates in the U.S. varied widely across AML subtypes (Table 38-1). The highest incidence rates were for the least specific AML subtype - AML, NOS (incidence rate (IR) for all races combined = 2.74/100,000 person-years), and incidence rates were intermediate for AML with myelodysplasia-related changes (IR = 0.45), acute myelomonocytic leukemia (IR = 0.43), AML with t(15;17) (IR = 0.39), and acute monoblastic and monocytic leukemia (IR = 0.33). AML incidence rates were higher among males than females for nearly all subtypes, with gender disparities least evident for AML with t(15;17), particularly among Hispanic whites, blacks, and Asians/Pacific Islanders; AML with t(9;11); and therapy-related myeloid neoplasms.

There have been relatively few published studies of population-based incidence of myeloid neoplasms worldwide, with most assessing rates by gender but few including descriptions by race/ethnicity. Accounting for differences in disease classifications and distinct time periods of study, a male predominace is also generally described, with some exceptions. Among cases in the Haematological Malignancy Research Network diagnosed during 2004-2008 in the U.K., the overall male-to-female rate ratio of AML was 1.1, ranging from 1.9 for AML with core binding factor (e.g., AML with t(8;21) and AML with inv(16)) <1.0 for AML with MLL (11q23), therapy-related AML, and AML with t(15;17) (Smith et al., 2009). In the European HAEMACARE project, a male predominance (based on crude rates) was most notable in the nonspecific AML group (not otherwise specified) and only a slight male predominance was apparent for AML with multilineage dysplasia and evolving from MDS, whereas incidence of AML with recurrent genetic abnormalities predominated slightly among females compared to males (Sant et al., 2010). Similarly, in Burgundy, France, AML cases diagnosed during 1980-2004 and classified according to the WHO 2001 classification demonstrated a male predominance for most subtypes of AML, not otherwise specified, whereas AML with cytogenetic abnormalities predominated among females (male-to-female IR ratio 0.95), largely attributed to AML with t(8;21) and AML with t(15;17) (Maynadie et al., 2011).

Internationally, population-based incidence patterns for MDS by subtype should be interpreted with caution given changing classification schemes over time, as noted above. Among the SEER cancer registries, assessment of incidence rates by subtype of MDS is limited due to the majority of cases being categorized as MDS, unclassifiable or NOS (Table 38-1). As with other myeloid malignancies (Craig et al., 2012), underreporting of MDS to cancer registries has been described (McQuilten et al., 2014), but in addition underdiagnosis is suspected based on many cases of nonspecific anemia that may not undergo evaluation or may not receive a definitive diagnosis (Goldberg et al., 2010, Cogle, 2015). Considering these caveats, MDS incidence rates in the U.S. (Table 38-1) were higher among males than females, overall and by race, and across all subtypes, with the exception of MDS with associated 5q deletion. For MDS overall, a similar male predominance was observed in the HAEMACARE (Sant et al., 2010) database and in the Haematological Malignancy Research Network (Smith et al., 2009, Smith et al., 2011).

In the U.S., MPN incidence rates were highest for total CML (IR = 1.69), polycythemia vera (IR = 1.51), and essential thrombocythemia (IR = 1.33). Across all races, incidence of MPN and MDS/MPN subtypes was higher among males than females, with the notable exception of essential thrombocythemia, which was associated with significantly lower incidence among males than females. In the HAEMACARE database, where MPN were grouped somewhat differently than in Table 38-1, as a group, MPN crude incidence rates were higher among males (IR = 3.5) than females (IR = 3.18), with the greatest gender disparity noted for CML, in contrast to other specified MPN subtypes considered as a group (Sant et al., 2010). In the U.K., CML and primary myelofibrosis were both associated with nearly 2-fold higher incidence rates among males than females in the Haematological Malignancy Research Network in contrast to chronic myeloproliferative neoplasm (ICD-O-3 code 9960) which was associated with a significantly lower incidence rate among males than females (Smith et al., 2009).

Age-specific incidence patterns differ between myeloid entities (Figure 38-3) and within disease subtypes (Dores et al 2012, Srour et al 2016). AML associated with recurrent genetic abnormalities had a constant incidence throughout life, whereas incidence of AML without without recurrent genetic abnormalities increased with advancing age, likely reflecting an accumulation of genetic mutations over a lifetime. Incidence of MDS increased exponentially with age, a pattern that supports accumulated genetic insults over a lifetime. In contrast, CML, the majority of cases likely to be associated with *BCR-ABL1*, has a pattern similar to that of AML with recurrent cytogenetic abnormalities, with a less pronounced rise in incidence with increasing age.

[Figure 38-3 here]

**<2> SURVIVAL: MYELOID NEOPLASMS**

Five-year relative survival differs markedly across myeloid neoplasms (Figure 38-4) and disease subtypes (Dores et al 2012, Srour et al 2016). AML, NOS is associated with the least favorable survival; CML and MPN are characterized by the most favorable survival; and AML with recurrent genetic abnormalities, MDS, and MDS/MPN have intermediate survival. Among males and females, younger (<60 years) individuals fare better than older (>60 years) individuals irrespective of myeloid entity considered. Worldwide, the CONCORD-2 study reported age-standardized 5-year net survival for adult leukemia of 50-60% in 21 countries in North America, west Asia, Europe, and Oceania, with lower survival in East Asia (19-23%) (Allemani et al., 2015). In Europe, cases reported to the HAEMACARE and EUROCARE databases, from 1997-2008, had significant improvement in 5-year relative survival for AML (excluding AML with t(15;17)), AML with t(15;17), CML, and MPN between 1997-1999 and 2006-2008. During 2006-2008, MPN (excluding CML) (74.9%) and acute promyelocytic leukemia (or AML with t(15;17)(q22;q12)) (61.9%) were associated with the most favorable survival, CML (54.4%) and MDS (48.8%) with intermediate survival, and AML (excluding AML with t(15;17)) (14.8%) with the least favorable survival (Sant et al., 2014). Notably, while AML with t(15;17) has a long-term favorable survival, it continues to have an early death rate (within 1 month of diagnosis) related to hemorrhagic complications from disseminated intravascular coagulation classically associated with this subtype of AML (Park 2011, Lehmann 2011, Dores 2012). Age (with older age having worse prognosis) and cytogenetics are among the most important prognostic factors for AML (Grimwade, 2001; Grimwade et al., 2010; Wheatley et al., 2009; Rollig et al., 2011, Schlenk et al., 2008, Patel et al., 2012). Prognostic features in MDS are often defined according to the original and revised International Prognostic Scoring Systems (IPSS, IPSS-R) which include bone marrow blast percentage, karyotype, and peripheral blood cytopenias (anemia, thrombocytopenia, neutropenia) (Greenberg et al., 1997; Greenberg et al., 2012; Voso et al., 2013; Ades et al., 2014). Although several disease-specific prognostic algorithms exist for the MPN, older age remains a universally poor prognostic feature (Sokal et al., 1984; Barbui et al., 2011; Passamonti et al., 2004, 2008; Tefferi and Pardanani, 2015).

[Figure 38-4 here]

**<1> PHYSICAL AGENTS**

**<2> IONIZING RADIATION**

**<3> Mechanisms of leukemogenesis**

Exposure to ionizing radiation, a clastogen and well-studied risk factor for myeloid neoplasms, causes acute and long-term effects in the hematopoietic compartment (Fleenor et al., 2015). Radiation-associated leukemogenesis has been attributed primarily to interaction of radiation with DNA, either directly via ionization or indirectly via free radicals, that results in radiation-induced DNA double-strand breaks. Cells with DNA damage initiate a repair response that differs between cycling and quiescent HSCs. Cycling HSCs preferentially initiate DNA repair by the homologous recombination pathway, and quiescent HSCs utilize the more error-prone non-homologous end-joining pathway. Thus, after irradiation, some HSCs may be characterized by radiation-induced genomic aberrations (Fleenor et al., 2015). Although more than 90% of double-strand breaks are repaired within 24 hours, the small fraction of misrepaired breaks can lead to chromosomal translocations and deletions (Tucker, 2010). Radiation-related translocations demonstrate the greatest persistence of all types of chromosomal exchange and damage, and may remain present for decades.

There is no gold-standard radiation signature or biological measure of radiation dose, but quantitative measurement of chromosome translocations in peripheral blood lymphocytes using fluorescence *in situ* hybridization (FISH) may reflect radiation dose as well as initiating radiogenic events that lead to radiation-induced leukemia (Tucker, 2010). Translocations may also represent a biomarker of effect because they have been found in most types of neoplasms (Kaye, 2009). Chronic or highly fractionated radiation exposure may result in accumulation of translocations in HSCs unless selective pressure removes these cells via such mechanisms as apoptosis, senescence, or differentiation (Fleenor et al., 2015). It is hypothesized that HSCs with deleterious mutations are removed and cells with advantageous mutations are selected and preferentially expanded. In recent years, mouse models have provided valuable data on genomic changes associated with radiation exposure, including genomic rearrangements, deletions, and changes in methylation (Rivina et al. 2014).

**<3> Individual and combined groupings of myeloid and other hematopoietic disorders and ionizing radiation**

AML is the hematopoietic malignancy most commonly associated with many forms of moderate-to-high ionizing radiation exposure (Boice, 2006). Results from the follow-up study of atomic bomb survivors (Hsu et al., 2013), and, to a lesser extent, epidemiological data from other radiation-exposed populations, also reveal increased risks of CML (Muirhead et al., 2009; Leuraud et al., 2015) and ALL (Hsu et al., 2013) associated with radiation exposure. The epidemiological findings for all leukemias other than CLL (hereafter designated non-CLL leukemias) are described in this section because AML, CML, and ALL are often considered as a combined entity in radiation studies, and radiation-related risks are frequently not quantified for the individual leukemic entities.

**<3> Medical radiation**

***<4> Evolution of medical radiation exposure and changing technologies***

During the past few decades, there have been dramatic changes in medical sources of radiation exposure (NCRP, 2009), mostly due to higher dose diagnostic procedures such as computed tomography (CT) scans as well as nuclear medicine studies, and fluoroscopically-guided interventional procedures, in addition to standard radiographic (x-ray) examinations. The rapidly growing use of these and other diagnostic and treatment modalities has resulted in a 6-fold increase in medical sources of radiation. Relatively few studies have evaluated cancer risks, including myeloid neoplasms, in patients undergoing these procedures or workers performing or assisting with these newer procedures. Exposure data reported in most surveys are estimated effective doses (defined as the sum of equivalent doses to organs and tissues exposed, each multiplied by the appropriate tissue weighting factor). Although absorbed radiation dose is a preferred measure, the effective dose is an approximate measure that enables a rough comparison across different types of radiological procedures. Typical effective doses for standard radiographic examinations range from 0.01 to 1.5 millisieverts (mSv); dental radiography 0.005-0.2 mSv; diagnostic fluoroscopy procedures 0.7-18 mSv; CT scans 2-20 mSv; nuclear medicine procedures 0.3-20 mSv; and interventional procedures 5-70 mSv (Mettler et al., 2008).

The clinical indications for and the practice of radiotherapy also have undergone notable changes over the past decades, including advanced imaging to produce more accurate determination of tumor volumes and spatial relationships with surrounding tissues, three-dimensional treatment planning systems, and newer modalities of three-dimensional conformal radiation therapy. Implementation of newer forms of radiotherapy have led to an increase in radiation dose to the tumor target, while reducing/minimizing the volume and dose to surrounding normal tissue structures, although some newer technologies may include a larger volume of normal tissue within the irradiated field that receives low doses (Thariat et al., 2012) (see Chapter 13).

***<4> Diagnostic radiologic examinations***

Although most epidemiologic studies evaluating the association of diagnostic x-rays and risk of myeloid leukemia have relied on questionnaire data, a few have assessed the association using radiologic examinations or medical records. In a large case-control study in a health maintenance organization in which over 25,000 x-ray procedures were abstracted from medical records and each procedure was assigned a score based on estimated bone marrow dose, the investigators found a small, non-significant elevation in risk (but no dose-response) using a 2-year lag, but no increase using a 5-year lag (Boice et al., 1991). Among patients diagnosed with AML during 1987-1994 in Los Angeles, an interview- and medical record-based study that utilized a unique database of estimated doses and dose ranges based on dosimetry literature and consultation with a radiology expert (Preston-Martin and Pogoda, 2003), found no association between diagnostic x-rays and risk of adult AML (Pogoda et al., 2011). However, radiographic procedures of the gastrointestinal tract and multiple spinal x-rays were linked with increased risk of CML in a case-control study in Los Angeles (Preston-Martin et al., 1989). Three of four earlier studies of CML and diagnostic radiographic procedures (two based on medical records) reported small increases in risk and one found a dose-response relationship with increasing numbers of x-rays in the 20 years prior to diagnosis. Inconsistent findings in the limited numbers of epidemiologic studies and potential methodologic limitations, along with the relatively small numbers of substantially exposed non-CLL leukemia cases preclude drawing firm conclusions regarding the association between diagnostic x-rays and leukemia risk (Linet et al., 2012).

Risks of myeloid leukemias have been evaluated in relation to diagnostic examinations from radiation sources other than x-rays. Chronic low-dose alpha-particle radiation from injections with the radiographic contrast medium, Thorotrast, which was used in earlier decades for cerebral angiography and for radiologic visualization of other vascular structures, has been consistently associated with increased risk of MDS and AML, considered jointly as (MDS/AML) (IARC, 2001; Travis et al. 2003). During 1928-1954, between 2.5 and 10 million patients worldwide were injected with Thorotrast. The estimated average dose to bone marrow was 100 mGy from an injection of 25 ml. Elevated risk of MDS/AML persisted for 8-50 years after exposure (Travis et al., 2003), and cumulative risk ranged from 129-140 MDS/AML cases/104 persons per Gy (IARC, 2001).

***<4> Therapeutic radiation for benign conditions***

Elevated risks of myeloid neoplasms have been reported in patients with benign conditions who underwent radiation treatment. X-ray radiation treatment for ankylosing spondylitis was associated with a 7-fold increase in non-CLL leukemia during a period of 1-25 years after exposure to a uniform bone marrow dose of 1 Gy; leukemia risk peaked within 10 years of exposure (Weiss et al., 1995). Somewhat lower AML excesses (relative risks ranging from 1.2 to 3.2) have been associated with radiation therapy treatments for benign gynecologic disorders (Sakata et al., 2012), peptic ulcer (Griem et al., 1994), and tinea capitis (Shore et al., 2003). The ongoing use of radiotherapy to treat benign ocular conditions, musculoskeletal diseases, inflammatory and proliferative disorders, and benign vascular proliferations demonstrates the need to follow-up these patients, particularly if treated at younger ages (McKeown et al., 2015). Higher risks and corresponding greater concern is associated with use of radiation therapy for benign tumors and other benign conditions in children and those with tumor predisposing syndromes (Evans et al., 2006). Myeloid leukemia and AML risks were also almost 4-fold increased among patients with ankylosing spondylitis treated with radium-224, with a mean estimated dose to the skeleton of 0.67 Gy (Wick et al., 2008).

***<4> Therapeutic radiation for malignant conditions***

Two-fold increased risks of t-MDS/AML have been described in patients treated with total body irradiation as part of a preparative regimen for transplantation and in those receiving radiotherapy for non-Hodgkin lymphoma, testicular cancer, uterine cervix cancer, uterine corpus cancer, and Ewing’s sarcoma (Wright et al., 2010; NCRP, 2011). t-MDS/AML following treatment of testicular cancer has been linked with both radiotherapy and platinum chemotherapy (Howard et al., 2008). t-MDS/AML following radiotherapy is often diagnosed within five years of exposure, with most cases occurring within 10-15 years (NCRP, 2011). Excess risks of t-MDS/AML following radiotherapy have been associated with estimated bone marrow doses ranging from 1 to 15 Gy for adults (and often higher doses for children), and risks do not continue to increase further at very high doses, perhaps due to cell killing. (Boice et al., 1987). Risks appear to be greater when large volumes of bone marrow are treated with lower doses or dose fractions. More evidence is needed on risks at higher doses (see Chapter 60).

**<3> Atomic bomb survivors**

Long-term studies of Japanese atomic bomb survivors have provided the most important population-based quantitative risk assessment for the risk of leukemia and other cancers associated with ionizing radiation. Studies of this population are the primary basis for international radiation risk protection measures (NRC BEIR VII, 2006) (see Chapter 13). Atomic bombs detonated over Hiroshima and Nagasaki in August 1945 resulted in many thousands of immediate and short-term deaths. At the end of the 1940s an excess of leukemia was apparent among the Japanese atomic bomb survivors. A long-term mortality follow-up of a population-based cohort of survivors, designated the Life Span Study, was launched with ascertainment of deaths since 1950. Follow-up of the Life Span Study cohort for cancer incidence was undertaken beginning in 1958 when population-based cancer registries were established in Hiroshima and Nagasaki (Mabuchi et al., 2011).

Results of dose-response for leukemia mortality from 1950 through 1982 and leukemia incidence from 1958 through 1987 have been previously summarized (Boice, 2006; Linet et al., 2006; Mabuchi et al., 2011). Among 113,011 Life Span Study cohort members followed through 2001, 371 incident non-CLL leukemias were ascertained, including 176 AML, 75 CML, and 43 ALL (Hsu et al., 2013). A nonlinear, upward curving dose-response pattern observed for non-CLL leukemias derived primarily from results for AML. Overall, the excess relative risk per Gray (ERR per Gy) for AML using the preferred quadratic model was 1.11, 95% confidence interval (CI) = 0.53-2.08, and risks according to age at exposure were U-shaped. The high excess rates for those who were children or adolescents at the time of the bombings initially declined over time; however, the excess rates increased with attained age regardless of age at exposure. The overall ERR per Gy for CML using the preferred linear model was 5.24, 95% CI = 1.92-11.8. The temporal patterns for CML and ALL differed from AML. In the period 5-10 years after the bombings, the fraction of ALL and CML attribuTable 38-to radiation from the bombings among cohort members with >0.0005 Gy was 59% for the entire period (23% for ALL and 36% for CML). However, these two subtypes accounted for 80% (27% for ALL and 53% for CML) of the excess leukemias during 1950-1955, but only 22% (10% for ALL and 12% for CML) during 1991-2001. Hsu et al (2013) speculated that CML and ALL rates may have been even higher than 80% within the first five years after the bombings (1945-1949), prior to availability of systematically ascertained data. In contrast, the fraction of AML attribuTable 38-to radiation among cohort members with >0.005 Gy was 38% for the entire period studied. AML accounted for only 20% of the excess leukemias during 1950-55 but for 80% of the excess leukemias during 1991-2001. This temporal pattern for AML is markedly different from that observed subsequent to cytotoxic chemotherapy, where most of the excess t-AML occurs within 10 years of treatment (see below).

Richardson and colleagues were the first to evaluate leukemia mortality risks in atomic bomb survivors by subtype (Richardson et al., 2009). The investigators followed up mortality among 86,611 survivors during 1950-2000 and identified 310 deaths from all forms of leukemia. For AML mortality, the dose response pattern was best described by a quadratic dose-response function that peaked approximately 10 years after exposure, while CML and ALL demonstrated a linear dose-response that did not vary with time since exposure. Excess leukemia mortality risk persisted for more than five decades. In the most recent decade evaluated (1991-2000), 34% of leukemia deaths among those with radiation dose >0.005 Gy were estimated to be attribuTable 38-to radiation from the bombings.

MDS was first linked with radiation exposure in the late 1980s following a detailed histopathological review of myeloid malignancies among atomic bomb survivors (Matsuo et al., 1988). The first analysis, which was based on only 13 MDS cases, revealed a significant dose-response for MDS mortality; the excess relative risk was several times greater than that seen for all solid cancers combined (Shimizu et al., 1999). An assessment of MDS diagnosed during 1984-2004 in two populations of survivors in Nagasaki found a notably increased ERR per Gy of 4.3 (95% CI = 1.6-9.5) using a linear model based on 47 cases in the 22,245 survivors in the Life Span Study (compared with ERR per Gy = 1.11 95% CI = 0.53-2.08 for AML using the preferred quadratic model) and a significant excess based on 151 MDS cases in 64,026 survivors with known distance from the bomb hypocenter (Iwanaga et al., 2011). While the latency period to development of MDS cannot be accurately determined prior to the mid-1980s, a 40-year latency period was observed among survivors after the mid-1980s. This timeframe is similar to that of *de novo* MDS, but differs from the median peak latency of 4-6 years observed for t-MDS/AML (Bhatia, 2013). However, molecular characteristics of MDS in the atomic bomb survivors more closely resemble those of patients treated with alkylating agents, with 6 of 13 atomic bomb survivors with MDS having *AML1* gene mutations (Harada et al., 2003). Further study is needed to clarify the molecular features of MDS associated with different exposures.

**<3> Radiation workers**

Historically, the major categories of workers exposed to ionizing radiation include medical radiation workers (radiologists and radiologic technologists), nuclear industry workers, radium dial workers, miners (uranium and tin), flight crew, and military servicemen exposed to above-ground nuclear tests (Wakeford, 2009). Studies quantifying leukemia and other cancer risks in workers are important because the radiation exposures in these populations are protracted over decades, and these populations are monitored. Small radiation exposures are cumulative and, if associated with leukemia, could translate into meaningful numbers of patients with leukemia since there are millions of radiation workers. Results from radiation worker studies also contribute important information towards defining radiation protection measures (see Chapters 13 and 16). Furthermore, these studies are useful because findings can be extrapolated to the general population experiencing low-level protracted exposures to natural background radiation and repeated radiation exposures from diagnostic radiologic examinations. However, overall, interpretation of risks for cancer and other serious diseases in long-term studies of medical radiation workers is complicated by the dramatically declining radiation doses to workers over time (Linet et al., 2010). As with most occupational epidemiologic studies, information on potential confounders *(e.g.,* workers’ personal diagnostic radiological imaging tests, radiotherapy, smoking, and genetic characteristics) is lacking, and few studies of medical radiation workers include women (see Chapter 16).

A large excess mortality risk (approximately 10-fold) of leukemia was initially reported among U.S. radiologists in 1944 (March et al., 1950). Eight major cohorts of radiologists and radation technologists have been actively followed up for leukemia, other cancers, and chronic diseases (reviewed in Yoshinaga et al., 2004; Linet et al., 2010). Collectively, the eight retrospective cohort investigations have studied radiologists or radiologic technologists who first began working over a period spanning more than 80 years, including small numbers who first began working in the earliest years of the professions (e.g., between 1897 and 1926). Radiologists and x-ray technicians employed in the first half of the twentieth century experienced notably elevated leukemia mortality (no subtype information provided), with increased risks ranging from 6- to 8.8-fold among those first joining professional societies (a proxy for first working) before 1940. Significantly elevated risks of incident non-CLL leukemias were seen in U.S. radiologic technologists who worked 5 or more years before 1950. Incidence of total leukemia was significantly elevated in Chinese x-ray workers employed during 1950-1980. Among British radiologists entering the profession after 1921 and U.S. radiologists entering the workforce in 1940 or later, leukemia risks declined notably over time. There were no significant excesses in U.S. radiologic technologists who first worked after 1950 (Yoshinaga et al., 2004; Linet et al., 2010). Accurate estimation of risk per unit of radiation has been limited due to absence of comprehensive historical dose reconstruction and, particularly, absence of recorded individual badge doses in the earliest years when exposures would have been greatest. A recent comprehensive historical reconstruction of individual occupational radiation doses for the U.S. radiologic technologists cohort (Simon et al., 2014) provides a useful basis for estimating risks per unit dose for hematologic malignancies and other cancers, circulatory diseases, and cataracts.

Results from earlier studies of nuclear workers can be found elsewhere (Boice, 2006; Polychronakis et al., 2013). Because radiation exposures of nuclear workers are mostly quite low and myeloid neoplasms are rare, pooled studies including large numbers of workers have been the most informative. A 15-country study examining the relation between estimated cumulative occupational radiation dose and mortality risk of non-CLL leukemia in a population of 407,391 nuclear workers using a 2-year lag found an excess risk per Sievert (Sv) of 1.93 (90% CI = <0-7.14) based on 196 leukemia cases (Cardis et al., 2005). The mean cumulative dose was estimated to be 19.4 mSv. In a subsequent study of 308,297 monitored nuclear workers from three countries employed for at least one year and followed up during the period 1944-2005, risk of all non-CLL leukemias was significantly elevated using a 2-year lag (ERR per Gy = 2.96, 90% CI = 1.17-5.21) based on 531 leukemia cases (Leuraud et al., 2015). The mean cumulative occupational radiation dose across the three cohorts was estimated to be 15.9 mGy (range 0.0-1,217.5 mGy). The excess risk was primarily due to a significant increase of CML (ERR per Gy = 10.45, 90% CI = 4.48-19.65 based on 100 cases), whereas positive risk estimates for AML (ERR per Gy = 1.29, 90% CI = -0.82-4.28 based on 254 cases) and for ALL (ERR per Gy = 5.80, 90% CI = not evaluable lower bound-31.57, based on 30 cases) did not contribute notably to the overall risk. In contrast to the low-level radiation exposures of most nuclear workers, external radiation exposures were high (mean cumulative dose of 800 mGy) for workers at the Mayak plutonium production facility in the Russian Federation during the early years of operation (1948-1958). An elevated risk of non-CLL leukemias (ERR per Gy = 0.99, 95% CI = 0.45-2.12) was associated with external radiation exposures using a 2-year lag. Risk from doses received 3-5 years prior to diagnosis of non-CLL leukemia was more than 10 times higher than the risk from doses received more than five years before diagnosis (Shilnikova et al., 2003). There was no evidence of an association of plutonium exposure with non-CLL leukemia in this population. Following the Chernobyl nuclear accident in 1986, clean-up operations were carried out for years after the accident. The early clean-up workers (also known as liquidators) experienced higher doses (mean cumulative radiation dose of 92 mGy) than most other nuclear workers (mean cumulative dose of 20 mGy). In a nested case-control study of leukemia in a cohort of 110,645 Chernobyl clean-up workers from Ukraine, a significant linear dose-response was observed for all leukemias based on 117 cases (ERR per Gy = 2.38, 95% CI = 0.49-5.87) (Zablotska et al., 2013). Unexpectedly, in this study risks were significantly elevated for CLL (ERR per Gy = 2.58, 95% CI = 0.02-8.43) as well as for non-CLL leukemias (ERR per Gy = 2.21, 95% CI = 0.05-7.61); 16% of the leukemias diagnosed in this population (18% of CLL and 15% of non-CLL leukemias) were attributed to radiation exposure. The CLL cases in this study did not have unique features. MDS cases have been described in Chernobyl clean-up workers, but radiation-related risks have not been reported (Gluzman et al., 2015).

Epidemiologic studies of uranium miners (Tomasek et al., 1993; Darby et al., 1995; Mc Laughlin, 2012; Zablotska et al., 2014) have shown no overall association of cumulative radiation dose with leukemia mortality, although leukemia mortality risk was increased within 10 years of first exposure (Darby et al., 1995). Studies of radium dial painters who experienced excess risks of osteosarcomas and cancers of the nasal sinuses, have found no clear evidence of excess risk of myeloid neoplasms (Boice, 2006), although in males occupationally exposed to radium, there is some evidence of an excess of leukemia, particularly of the same subtype(s) as seen in patients who received Thorotrast (Stebbings, 1998).

Cancer risks have been evaluated in flight personnel. Excess risks of AML were described in Canadian airline pilots (Band et al., 1996) and in Danish cockpit crew flying more than 5,000 hours (Gundestrup and Storm, 1999), but pooled analysis of airline crew cohorts from 10 countries found no evidence of elevated myeloid leukemia risk (Hammer et al., 2014).

A critical question that is difficult to address in a single epidemiological study is the risk of non-CLL leukemia following low-dose, protracted radiation exposure. In a meta-analysis addressing this question, Daniels and Schubauer-Berigan modeled results from 10 studies that were cohort or nested case-control in design, reported quantitative estimates of exposure, were screened to reduce information overlap, and analyzed data using relative or excess relative risk per unit of radiation exposure (Daniels and Schubauer-Berigan, 2011). These investigators estimated an excess relative risk at 100 mGy of 0.19 (95% CI = 0.07-0.32) after adjusting for publication bias. They found no evidence of between-study variance. The excess relative risk estimate was in agreement with the non-CLL leukemia risk from the Life Span Study of the atomic bomb survivors.

**<3> Military workers exposed to nuclear weapons tests and to depleted uranium**

Military participating in maneuvers during nuclear weapons testing have been evaluated in a series of epidemiologic studies (reviewed in Boice, 2006). An excess of leukemia mortality (based on 10 cases), but not total cancer mortality, was reported among approximately 3,000 military participants during a 1957 nuclear test in the U.S. (Caldwell et al., 1980). Among approximately 70,000 U.S. military personnel who participated in one of five nuclear tests during the 1950s, a non-significant increase in risk for leukemia mortality was observed (IOM, 2000). A study of 21,357 U.K. military participants reported an increased relative risk of non-CLL leukemia mortality but noted that this may have reflected a reduced risk in controls (Muirhead et al., 2003). None of these studies, or others, included estimated radiation doses. Using recently available digital records, Till and colleagues have undertaken dose reconstruction for a planned case-cohort study of leukemia and male breast cancer in a cohort of 115,000 U.S. military participating in eight nuclear test series. The investigators have reported estimated median radiation doses ranging from 9.5 to 24 mGy, and further study is underway (Till et al., 2014).

Based on concerns raised about a possible association of leukemia among military exposed to ammunition reinforced by depleted uranium, Storm and colleagues studied 13,552 men and 460 women deployed to the Balkans during 1992-2001 and followed up through 2002. These investigators found no excess of leukemia (Storm et al., 2006), but the size of the population may have been too small to detect modest to moderately elevated risks.

**<3> Environmental radiation**

Few studies have examined radon or natural background radiation and risk of leukemia. While an ecological study suggested a correlation between indoor radon exposure and myeloid leukemia (Henshaw et al., 1990), a subsequent comprehensive and critical review concluded that there was little evidence of a link (Laurier et al., 2001). An intriguing investigation that evaluated approximately 80,000 sTable 38-residents residing in underground dwellings in China who experienced about three-fold higher cumulative radiation levels (6.4 mSv) than the average population worldwide, found no evidence of an increase in leukemia (Wei and Sugahara, 2000). Among the limited numbers of studies of radon or of natural background radiation and leukemia, most have examined pediatric leukemia. Most of the studies of adult leukemias have been ecologic in design, few have included individual measurements, and those with measurements have been underpowered given the low radiation exposure levels (Boice, 2006).

Data are also limited on cancer risks associated with environmental exposures to manmade sources of radiation. A population of approximately 30,000 persons residing in villages next to the Techa River was exposed to chronic external and internal radiation during 1950-1960 from releases from the Mayak nuclear weapons plutonium production plant in the Russian Federation. The median cumulative red bone marrow dose was 0.2 Gy, but doses ranged up to 2 Gy. In a follow-up during 1953-2005, a significant dose-response relationship was seen for non-CLL leukemia, with an estimated excess relative risk of 4.9 (95% CI = 1.6-14.3) based on 70 cases. No excess risk or dose-response relationship was observed for CLL (Krestinina et al., 2010).

Spurred by a report from the U.K. of increased risk of leukemia and lymphoma occurring among young persons residing in proximity to nuclear plants, many ecologic studies and a few analytic epidemiologic studies have been conducted. Most of the studies have focused on childhood leukemia (Laurier et al., 2008). A large ecologic investigation examined total and specific forms of adult cancers, including leukemia, but found no association (Jablon et al., 1991). Limitations acknowledged by the authors included lack of radiation dose measurements, absence of information about potential confounders, and the likely underpowered nature of the study despite including a large population base of more than 900,000 cancer deaths from 1950 through 1984 (Jablon et al., 1991). A borderline significant increase in risk of non-CLL leukemia and of ALL was observed in a case-control study of more than 1,000 leukemia deaths among persons living in southwest Utah in proximity to the Nevada Test Site (Stevens et al., 1990), with significantly elevated risks for those exposed to fallout under 20 years of age.

**<2> NON-IONIZING RADIATION – EXTREMELY LOW-FREQUENCY MAGNETIC FIELDS AND RADIOFREQUENCY**

**<3> Exposures and biological effects from extremely low-frequency magnetic fields**

Electromagnetic fields are produced by a growing number of sources that are ubiquitous worldwide. Extremely low-frequency magnetic fields are produced from the generation, transmission, and use of electricity. Microwaves are generated by radio and television transmission, microwave ovens, mobile telephones and base stations, wireless local area networks, and smart meters (SCENIHR, 2015) (see Chapter 15 for more details). The primary known biological effect of electromagnetic fields is tissue heating. Electromagnetic fields generate energy that is proportional to the frequencies emitted (measured in hertz), and the energy they produce is too weak to break chemical bonds or to cause translocations in DNA. To date, laboratory studies have failed to demonstrate consistent, reproducible evidence of carcinogenicity, with the possible exception of a co-carcinogenic effect of radiofrequency fields and a chemotherapy agent (see Chapter 15). Exposures largely have been studied in residential settings, in which most studies have assessed risks of pediatric leukemia and brain tumors (see Chapters 15 and 59), or in occupational settings.

**<3> Residential exposures to extremely low-frequency magnetic fields**

Residential investigations of extremely low-frequency magnetic field exposures in Nordic countries based on calculated historic exposures have shown no evidence of a significant increase in risk of leukemia in adults in Finland (Verkasalo et al., 1996) or Norway (Tynes and Haldorsen, 2003), but a borderline increase in risk of AML and CML among persons residing in homes exposed to the highest estimated fields in Sweden (Feychting and Ahlbom, 1994). Risk of AML was not increased in adults residing in homes with measured exposures to extremely low-frequency magnetic field levels in western Washington state (Severson et al., 1988) nor was risk of total leukemia elevated in persons living in close proximity to high power lines in the U.K. (Elliott et al., 2013).

**<3> Occupational exposures to extremely low-frequency magnetic fields**

Most epidemiologic studies of myeloid leukemia (or brain tumors) in workers considered to have high exposure to extremely low-frequency magnetic fields (*e.g*., power linemen, utilities workers, and electronics workers) haveused job titles and/or a job exposure matrix as proxy measures of exposure (see Chapter 16). A few studies that incorporated measurements, as reviewed earlier, reported inconsistent findings for AML (Linet et al., 2006). A meta-analysis published in 1997, which described an overall 40% increase in risk of AML among workers in jobs with high extremely low-frequency magnetic field exposures (Kheifets et al., 1997), was updated a decade later and reported a lower pooled estimate for AML (pooled relative risk (RR) = 1.09, 95% CI = 0.98-1.21) in this population (Kheifets et al., 2008). Risk for CML was also lower in the more recent meta-analysis (RR = 1.11, 95% CI = 0.94-1.31) compared with the earlier one (RR = 1.24, 95% CI = 0.98-1.57). Based on these results, Kheifets and colleagues concluded that the lack of a clear pattern of extremely low-frequency magnetic field exposures and risks for AML, CML, and other leukemia subtypes did not support the hypothesis that these exposures were responsible for the observed excess risks. Subsequent to the 2008 meta-analysis, an update of a cohort study of Danish utility workers found no evidence of increased risk of total leukemia (Johansen et al., 2007), while a population-based cohort study in the Netherlands that utilized a job exposure matrix found a dose-response relationship with estimated low and high exposure to extremely low-frequency magnetic fields and AML (Koeman, 2014).

**<3> Radiofrequency exposures**

There is little evidence that myeloid neoplasms are increased among people using mobile telephones or living in proximity to base stations (IARC, 2013). There are few epidemiologic studies of workers exposed to radiofrequency fields, and some of the results are difficult to interpret. In general, risks of leukemia overall and myeloid leukemia were not increased (IARC, 2013). An exception was an elevated risk of AML mortality among aviation electronics technicians (RR = 2.60, 95% CI = 1.53-4.43, based on 23 deaths) (Groves et al., 2002). In this same cohort, a non-significant increase in AML (RR = 1.87, 95% CI = 0.98-3.58) was observed among 20,109 U.S. Navy personnel who served on ships during the Korean War and were characterized as having high radiofrequency exposure based on expert assessment.

**<1> CHEMICAL EXPOSURES: MANUFACTURING, FARMING, MEDICATIONS**

**<2> MANUFACTURING**

**<3> Benzene**

Benzene has been used for more than a century as a key component in the manufacturing of shoes, leather, rubber goods, paints, dyes, inks, lubricants, detergents, pesticides, and pharmaceuticals, and more recently in the production of styrene, polymers, latexes, hydroquinone, benzene hexachloride, plastics, resins, and insecticides (IARC, 2012). Jobs in crude oil refining and in sea and land transport of crude oil and gasoline also involve exposure to benzene, as do jobs in auto repair and bus garages. Surveys have led to estimates of more than 2.1 million benzene-exposed manufacturing workers worldwide. Exposure sources to benzene in the general population include motor vehicle exhaust, tobacco smoke, contaminated water and foods, gasoline at pumping stations, and leaking underground gasoline storage tanks.

In 1982 the International Agency for Research on Cancer (IARC) concluded that there was sufficient evidence linking benzene with leukemia, particularly AML. The updated assessment by IARC noted that cohort studies in multiple industries and different countries demonstrated a dose-response pattern for AML (IARC, 2012). Myeloid and lymphoid neoplasms, as well as many other types of cancer, also have been described in mice and rats following benzene exposure (IARC, 2012). A systematic review and meta-analysis of four studies focusing on cumulative exposure to benzene in humans found evidence of a dose-response pattern, with 3.2-fold relative risk of AML for benzene exposure levels >100 ppm-years, although the trend was not statistically significant (Khalade et al., 2010). Data on AML risk at low levels of benzene exposure have been relatively limited due to small numbers of cases available for study. Among Chinese benzene-exposed workers with cumulative exposures less than 40 ppm-years, risks of AML (RR = 1.9, 95% CI = 0.5-7.0, based on 5 cases) and the combined category of MDS/AML (RR = 2.7, 95% CI = 0.8-9.5, based on 7 cases) were non-significantly increased (Hayes et al., 1997). In a pooled and updated analysis of three nested case-control studies carried out among cohorts of petroleum distribution workers with low levels of benzene exposure from Australia, Canada, and the U.K., AML risks rose modestly, but not significantly, with increasing cumulative level of benzene exposure (<0.348 ppm-years: odds ratios (OR) = 1.00 [referent], based on 20 cases; 0.348-2.93 ppm-years: OR = 1.04, 95% CI = 0.50-2.19, based on 19 cases; >2.93 ppm-years: OR = 1.39, 95% CI = 0.68-2.85, based on 21 cases). A similar relationship was observed for duration of exposure and peak exposure, but there was no clear pattern for average or maximum intensity of exposure. Risks were non-significantly increased (OR ranged from 1.35 to 1.90) in the top quartiles of average and maximum exposure, and increased in those with peak exposure <3 ppm (OR = 1.50, 95% CI = 0.82-2.75). Significantly elevated risks of AML were seen among those who had ever been tanker drivers (OR = 2.02, 95% CI = 1.08-3.28) (Schnatter et al., 2012; Rushton et al., 2014). MDS/AML was associated with recent (less than 10 years before diagnosis), but not distant (10 or more years before diagnosis) benzene exposure among Chinese benzene-exposed workers (Hayes et al., 1997). Data from the long-term follow-up of a cohort of U.S. Pliofilm workers suggest that the excess risk of leukemia diminished with time since exposure (Rinsky et al., 2002). In addition to AML, benzene also causes hematotoxicity at very low levels in benzene-exposed workers, even for exposures below 1 ppm in air (Lan et al., 2004). Some (Talbott et al., 2011; Raaschou-Nielsen et al., 2016), but not all (Wilkinson et al., 1999), studies have reported modestly increased risks of AML among community members exposed to gasoline vapors or traffic-related air pollution and among those who reside in proximity to oil refineries. Efforts are underway to understand the mechanisms underlying benzene-associated leukemogenesis by identifying the critical genes and pathways that are involved in inducing genetic, chromosomal, and epigenetic abnormalities and genomic instability in HSCs; altered proliferation and differentiation of the HSCs; and dysregulation of stromal cells (McHale et al., 2012). These effects are likely modulated by benzene-induced oxidative stress, reduced immunosurveillance, and aryl hydrocarbon dysregulation.

Data assessing an association between benzene and MDS are limited. Risks of mortality from MDS were significantly increased among benzene-exposed (7 cases) compared with unexposed workers (0 cases) among Chinese benzene-exposed workers followed up during 1972-1999 (Linet et al., 2015). Cumulative benzene exposure demonstrated a monotonic dose-response relationship and significant trend with increasing benzene dose and MDS in the pooled 3-country study of petroleum distribution workers (OR = 4.33, 95% CI = 1.31-14.3 at a cumulative exposure >2.93 ppm-years, based on a total of 29 cases with all levels of cumulative exposure) (Schnatter et al., 2012). Increased risks for MDS were observed among workers employed at terminal facilities (OR = 5.04, 95% CI = 1.58-16.1) and among tanker drivers (OR = 2.16, 95% CI = 0.79-5.88). Similar, albeit non-significant or borderline significant, dose-response patterns were observed for average exposure, maximum exposure, and peak exposures (>3 ppm) to benzene and MDS.

Based on relatively few studies, CML has not been consistently linked with benzene exposure (IARC, 2012; Khalade et al., 2010); however, a meta-analysis found a moderate increase in risk of CML in studies of benzene workers that commenced follow-up after 1970 (OR = 1.67, 95% CI = 1.02-2.74) (Vlaanderen et al., 2012). The broader category of MPN and benzene exposure has only been studied in the 3-country investigation (Glass et al., 2014). Dose-response trends for CML (based on 28 cases) and MPN (excluding CML) (based on 30 cases) were not statistically significant for cumulative, average, or maximum benzene exposure, although risks rose with increasing cumulative dose experienced 2-20 years before diagnosis. Among workers with cumulative exposure >2.93 ppm-years, risks were elevated for CML (OR = 12.6, 95% CI = 1.06-150) and for MPN excluding CML (OR = 4.22, 95% CI = 0.95-18.7) (Glass et al., 2014).

**<3> Formaldehyde**

Concerns have arisen about health effects, including leukemia, of formaldehyde associated with workplace (health care, embalming, and manufacturing workers) and general population exposures, the latter from formaldehyde levels in new homes. In follow-up of 25,619 manufacturing workers in 10 plants during 1966-2004, risk of myeloid leukemia was associated with peak formaldehyde exposures (Hauptmann et al., 2003; Beane Freeman et al., 2009). Myeloid leukemia risk was non-significantly elevated for highest vs lowest (≥4 ppm vs. >0-<2 ppm) peak exposure for the period of follow-up before 1966 through 2004 (RR = 1.78, 95% CI = 0.87-3.64, p-trend = 0.13). Risks were highest before 1980, but trend tests attained statistical significance only in 1990 when sufficient deaths had occurred. Risks were highest in the first 25 years following exposure and declined with continued follow-up. This pattern is similar to that observed for some other chemical exposures and AML risk (Linet et al., 2006).

Funeral industry workers as well as anatomists and pathologists may also be exposed to formaldehyde. Based on a follow-up during 1960-1986 of a cohort of embalmers identified from funeral directors’ associations and licensing boards, a nested case-control study of leukemia and selected other categories of cancer deaths was carried out. Compared with workers who performed fewer than 500 embalmings, those who performed more than 3,068 embalmings experienced an elevated risk (OR = 3.0, 95% CI = 1.0-9.2), as did those who performed embalmings for more than 34 years (OR = 3.9, 95% CI = 1.2-12.5). Risk of myeloid leukemia rose significantly with increasing number of embalmings performed, number of years of embalming, estimated lifetime formaldehyde exposure in ppm-years, and peak formaldehyde levels (Hauptmann et al., 2009). A study of 43 formaldehyde-exposed and 51 unexposed workers in China demonstrated numerical chromosomal aberrations in myeloid progenitor cells (including chromosome 7 monosomy and chromosome 8 trisomy) of the exposed workers consistent with MDS/AML; other changes were observed in peripheral blood reflecting bone marrow effects (Zhang et al., 2010). Although meta-analyses published in 2010 reported conflicting findings on the relationship between formaldehyde and myeloid leukemia (Schwilk et al., 2010; Bachand et al., 2010), more recent studies along with evidence of a biologically plausible mechanism led an IARC working group to conclude that evidence was sufficient to designate formaldehyde as causal for leukemia, particularly myeloid leukemia (IARC, 2012).

**<3> Styrene and butadiene rubber manufacturing**

Workers in the styrene and butadiene rubber manufacturing industry have been repeatedly found to have excess mortality of total leukemia, more recently determined to be mostly due to CML, CLL, and, to a lesser extent, myeloid neoplasms (IARC, 2008). Although the most recent follow-up data show only moderate excess risk of total leukemia, notable leukemia excesses were apparent in workers hired in the 1950s, those who were 20-29 years since hire, and those who had worked >10 years. Risks were increased in areas of the plants with higher exposures and in hourly workers, especially those hired in the 1950s when exposures were higher. There were no measurements available before the 1970s. Average levels of butadiene from the 1970s through much of the 1980s ranged from 8-20 mg/m3 while those from the 1990s to the present have generally been <2 mg/ m3. Dose-response relationships have been observed for butadiene with CML and with myeloid neoplasms (for cumulative exposures >425 ppm-years CML: RR = 7.2, 95% CI = 1.1-47.6 and total myeloid neoplasms including CML: RR = 2.4, 95% CI = 0.9-6.8) (Delzell et al., 2006), but estimates are imprecise due to small numbers of workers with specific leukemia subtypes. Evidence of carcinogenicity was considered to be sufficient for leukemia in workers in the styrene and butadiene rubber manufacturing and for butadiene (IARC, 2008). An IARC Working Group reaffirmed this conclusion as part of the comprehensive re-evaluation published in the IARC monograph 100f (IARC, 2012).

**<3> Farming, agricultural and related exposures**

As described previously, some studies of farmers and farm workers have shown modest excess risks of AML and virtually all other subtypes of leukemia (risks ranging from 1.1-to 1.4-fold), while others have shown no increase in risk of AML (Linet et al., 2006). International variation in risks may reflect differences in agriculture-related exposures such as pesticides (particularly animal insecticides and herbicides), fertilizers, diesel fuel and exhaust, or infectious agents (Blair and Zahm, 1995). Few earlier studies that reported increased risk of AML among those living on a farm (Sinner et al., 2005; Wong et al., 2009) evaluated specific pesticide exposures in relation to AML. In the Agricultural Health Workers cohort, excess risk of leukemia was associated with use of chlordane and heptachlor (Purdue et al., 2007), alachlor (Lee et al 2004), and the organophosphates fonofos (Mahajan et al., 2006) and diazinon (Beane Freeman et al., 2005). Myeloid leukemia was increased among 20,000 persons residing in Seveso and ages 0-19 years within 10 years after an industrial accident caused contamination of the region with 2,3,7,8-*tetrachlorobibenzo-p-dioxin* (Pesatori et al., 1993). Recent review of the evidence for dioxin does not support a strong association with myeloid leukemia (IARC, 2012). Biomarkers are needed that provide information about long-term exposure to pesticides and that assess their chronic effects. Few studies have evaluated farming or agricultural work and risk of MDS or MPN, and findings, to date, are inconsistent (Anderson et al., 2012).

**<2> MEDICATIONS**

**<3> Cytotoxic chemotherapy**

***<4> Overview***

Relative risks of developing t-MDS/AML following cytotoxic treatments are substantial (*e.g.*, ≥3-fold increased) and lifetime cumulative risks of t-MDS/AML range from <1 to 10% (Leone et al., 2010; Candelaria and Duanes-Gonzalez, 2015). Some t-AML are preceded by MDS, while others are not, and latency periods, although generally fairly short, differ according to the type of cytotoxic chemotherapy. Although data are limited on the changing occurrence of t-MDS/AML over calendar time, a 34-year assessment (1975-2008) of 426,068 adults treated with chemotherapy for first primary cancers in the population-based SEER Program demonstrated that there have been substantial changes in t-AML risks over time that are consistent with known changes in treatment practices (Morton et al., 2013). That study identified 801 cases of t-MDS/AML, a rate 4.7-fold higher than expected in the general population, with nearly half the cases occurring after breast cancer or NHL. Over the study period (1975-2008), t-MDS/AML risks following treatment of NHL rose steadily, but declined over the calendar year period following treatment of ovarian cancer and multiple myeloma. t-MDS/AML rates were highest during 1975-78 after treatment of primary breast cancer and Hodgkin lymphoma, then declined during the 1980s, followed by modest increases in the 1990s. Risks for t-MDS/AML were highest among those treated with chemotherapy for primary cancers at younger ages, although elevated risks were apparent regardless of age at treatment. Excess absolute risks of t-MDS/AML were highest following treatment of Hodgkin lymphoma and multiple myeloma; intermediate following treatment of lung and ovarian cancers and NHL; and lowest after treatment of breast cancer. Combination chemotherapy and radiotherapy was associated with non-significantly increased risks of t-MDS/AML after treatment of cancers of the lung, breast, and ovary, but not after treatment of lymphoproliferative malignancies. The 2008 WHO classification removed the distinction between alkylating agent-related and topoisomerase II inhibitor-related t-MDS/AML, but for etiologic purposes the literature on t-MDS/AML risks associated with these two categories of chemotherapy is discussed separately below.

***<4> Alkylating agents***

t-AML associated with alkylating agents generally occurs as a result of damage to DNA by methylation of DNA inter-strand crosslink formation. The main methylating forms of alkylating agents include procarbazine, dacarbazine, and temozolomide (Leone et al., 2010). Nitrosoureas and procarbazine are associated with a high risks of t-MDS/AML. For example, patients with Hodgkin lymphoma treated with MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) had an absolute risk of developing t-MDS/AML of 3.4% compared with 1.3% for Hodgkin lymphoma patients treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), a regimen that does not include procarbazine or nitrogen mustard. Busulfan and melphalan are linked with higher risk of t-AML than cyclophosphamide. As a result, cyclophosphamide has replaced busulfan and melphalan in several chemotherapy regimens.

The pathogenesis of t-MDS/AML is frequently characterized by a preleukemic phase, trilineage dysplasia, and cytogenetic abnormalities involving monosomy of chromosome 5 or deletion of 5q and/or monosomy of chromosome 7 or deletion of 7q. t-MDS or t-AML cases with monosomy of chromosome 17 or deletion of 17p, dicentric chromosomes, duplication or amplification of chromosome band 11q23 and other karyotypic abnormalities, but without abnormalities of chromosome 5 often have methylation of the *CDKN4B* gene promoter and somatic mutations of *RUNX1* (Leone et al., 2010). t-MDS and t-AML have been reported subsequent to Hodgkin lymphoma, NHL, multiple myeloma, polycythemia vera, and breast, ovarian, and testicular cancers treated with alkylating agents. Typically, t-AML occurs 5-7 years following treatment, and risk is related to cumulative alkylating drug dose.

***<4> Topoisomerase inhibitors***

Topoisomerase II inhibitors that bind to the enzyme/DNA complex at the strand cleavage stage of the topoisomerase reaction have been linked with elevated risk of t-AML (Nitiss, 2009). As a result of blockage of the enzyme reaction, topoisomerase II inhibitors may leave DNA with a permanent DNA strand break. The resulting treatment-related leukemias may be myeloid (with the partner gene of *MLL* being chromosome 9) or lymphoid (with the partner gene being chromosome 4) in lineage, and studies of gene expression profiles suggest that the leukemia originates within an undifferentiated hematopoietic stem cell.

Both the antineoplastic effect and the leukemogenic effect of topoisomerase II inhibitors are due to chromosome translocation. Drugs that interact with topoisomerase II include epipodophyllotoxins that intercalate (e.g., doxorubicin) and those that do not intercalate (e.g., etoposide, teniposide). With the more recent widespread clinical use of topoisomerase II inhibitors, including anthracyclines (e.g., doxorubicin, daunarubicin) and anthracenedione (e.g., mitoxantrone), elevated risks of t-AML have been observed and risks appear to be higher among those treated at younger ages. The resultant t-AML is generally not preceded by MDS, develops after a shorter latency period (median latency typically 2-3 years), and has different cytogenetic abnormalities than alkylating agent-associated t-AML. Another contrast with alkylating agent-associated t-AML is the association of topoisomerase II inhibitors with balanced translocations involving the *MLL* gene on chromosome band 11q23 (Cowell et al., 2012). Most *MLL* rearrangements are reciprocal translocations with many different partner genes including t(9;11) or t(4:11) but also include internal duplications, deletions, or inversions. Questions about the relationship between cumulative dose and frequency of treatment with epipodophyllotoxins with risk of t-AML remain, as some previous studies were limited by the use of chemotherapeutic regimens that include both topoisomerase II inhibitors and alkylating agents.

***<4> Other chemotherapy agents***

Platinum agents (e.g., cisplatin, carboplatin, oxaliplatin) are similar to alkylating agents in their mechanisms of action and resistance with the exception that they do not alkylate DNA but rather form covalent metal adducts with DNA (Chabner et al., 2011). Increasing doses of platinum-based chemotherapy for ovarian (Travis et al., 1999) and testicular cancers (Howard et al., 2008) have been quantitatively associated with increasing risks for t-AML. A 10-fold higher risk of t-MDS/AML has been observed in breast cancer patients treated with mitoxantrone and methotrexate (an antimetabolite) or methotrexate and mitomycin C (an antibiotic that inhibits DNA synthesis) (Saso et al., 2000).

Antimetabolites, including methotrexate, azathioprine, 6-thioguanine, and fludarabine (a nucleoside analogue), are used for some cancer treatments, as immunosuppressants in autoimmune diseases, or in recipients of organ transplants, the latter often including combination treatment with cyclosporine A and steroids. The antimetabolites share structural similarities with nucleotides and can be incorporated into DNA or RNA, thus causing inhibition of cell proliferation. Increased risks of AML have been reported in patients treated with azathioprine after organ transplantation or for autoimmune disease (Yenson et al., 2008). Leukemia risks may be higher in patients with low thiopurine S-methyltransferase activity, and mechanisms may include aberrant mismatch repair and microsatellite instability (Karran, 2006). t-MDS/AML is increased among patients treated with nucleoside analogs (*e.g.,* fludarabine, cladribine), alone or in combination with other agents (e.g., with chlorambucil or cyclophosphamide) often used to treat patients with CLL and other lymphoproliferative neoplasms (Leone et al., 2010). t-MDS/AML has also been associated with pretransplantation chemotherapy (*e.g*., mechlorethamine, chlorambucil) and/or transplantation conditioning treatments that include total body irradiation, particularly at doses >12 Gy (Metayer et al., 2003).

***<4> Transformation of MPN to t-AML: role of single vs multiple treatments or other factors is unclear***

MPN, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, can “transform” to AML (Abdulkarim et al., 2009). There is variability in the risks of developing AML after different forms of MPN (Barbui, 2004; Mesa et al., 2005; Passamonti et al., 2008). Mechanisms involved in leukemic transformation are not well understood, particularly because of the rarity of the event, the difficulty of disentangling the role of one or more treatments, and the likelihood that that the causes of transformation are multifactorial. For example, in a nationwide Swedish cohort of 11,039 MPN patients diagnosed during 1958-2005, 292 patients developed AML (n = 271) or MDS (n = 21) (Bjorkholm et al., 2011). A significantly increased risk of developing MDS/AML was observed among MPN patients who received ≥1,000 MBq 32P, but it was unclear whether those receiving this high dose of 32P had also received alkylating agents and/or hydroxyurea.

**<3> Other medications**

***<4> Chloramphenicol***

Use of chloramphenicol has long been linked with bone marrow suppression and risk of aplastic anemia (Fraumeni, 1967). Some patients with this hematological disorder have developed AML (Cohen and Creger, 1967), although risk of AML following use of chloramphenicol is unclear because rigorous epidemiological data are lacking (Fraumeni, 1967). A dose-response relationship was observed between use of chloramphenicol and risk of childhood AML and ALL in Shanghai (Shu et al., 1987), but studies in adults using medical or pharmacy records have shown no association (Doody et al., 1996) or a non-significant excess risk of acute leukemia (Traversa et al., 1998). Use of topical chloramphenicol was not significantly associated with risk of acute leukemia or AML based on data abstracted from general practitioner medical records in a large case-control study in the U.K. In this study, risk was non-significantly increased if topical chloramphenicol was used 3 or more times, but there was no significant dose-response relationship (Smith et al., 2000).

***<4> Non-steroidal anti-inflammatory drugs***

Clinical reports described leukemia following treatment with phenylbutazone, but high-quality epidemiologic studies are limited. In a prospective study of hematopoietic neoplasms in a health maintenance organization for which pharmacy records were the basis of information, there was no evidence of a significant association or a relationship with duration or cumulative amount of use of phenylbutazone and myelocytic leukemia (Friedman, 1982).

Limited data have linked use of non-steroidal anti-inflammatory drugs (NSAIDs) with risk of AML (Kasum et al., 2003), but findings generally show a modestly reduced risk. A case-control study in Los Angeles reported that use of NSAIDs was associated with a decreased risk of AML (Pogoda et al., 2005). Based on pharmacy records from the National Health System in the population-based case-control study in the Province of Rome, use of very high doses of NSAIDs was linked with a modest, non-significant reduction in risk of acute leukemia (Traversa et al., 1998). In case-control, interview-based studies in Buffalo (Weiss et al., 2006) and Minnesota (Ross et al., 2011), aspirin was associated with a decreased risk of AML, and acetaminophen was linked with an increased risk. NSAIDs are characterized by anti-inflammatory, anti-pyretic, and analgesic properties and target the COX enzymes, thus inhibiting prostaglandin synthesis, oxidative cell damage, angiogenesis, and potentially signal transduction pathways which are believed to influence risk of malignancy. The specific mechanism(s) that may affect risk of hematopoietic malignancies after NSAID exposure is unknown (Bernard et al., 2008).

**<1> LIFESTYLE FACTORS**

**<2> SMOKING**

Cigarette smokers are exposed to more than 70 chemicals that have been linked with cancer, including known leukemogens *(e.g.,* benzene, formaldehyde, and polonium-210) (CDC Surgeon General’s Report 2010). Since the early 1990s, a substantial number of studies have reported associations of cigarette smoking with AML. A recent meta-analysis of 23 studies that included 7,746 AML cases reported significantly elevated risks for current smokers (RR = 1.40, 95% CI = 1.22-1.60) and ever smokers (RR = 1.25, 95% CI = 1.15-1.36) (Fircanis et al., 2014). Risks were notably higher for those who had smoked for ≥20 versus <20 years and rose significantly with increasing number of cigarettes smoked per day and increasing number of pack-years smoked. A growing number of studies have evaluated cigarette smoking and risk of MDS. A meta-analysis of 14 studies that assessed 2,588 MDS cases found significantly elevated risks among current (RR = 1.81, 95% CI = 1.24-2.66) and ever (RR = 1.45, 95% CI = 1.25-1.68) smokers, along with higher risks among those who smoked for ≥20 versus <20 years, those who smoked ≥20 versus <20 cigarettes per day, and those with higher number of pack-years of smoking (Tong et al., 2013). Combining AML and MDS in a meta-analysis of 25 studies with 8,074 cases of myeloid neoplasms that overlapped with the above described meta-analyses, investigators found similar results for MDS/AML as for AML alone (Wang et al., 2015). Risks for MDS/AML were significantly increased for current (RR = 1.45, 95% CI = 1.30-1.62) and ever (RR = 1.23, 95% CI = 1.15-1.32) smokers and were higher for those who smoked ≥20 versus < 20 years, ≥20 versus <20 cigarettes per day, and a greater number of pack-years. The mechanisms by which cigarette smoking increases risk of MDS/AML are unknown. However, smoking has been shown to decrease circulating CD34 progenitor cells in healthy persons (Ludwig et al., 2010) as well as to decrease the number of erythrocyte and granulocyte colony-forming units, upregulate toll-like receptor expression, increase NF-kB, AKT, and ERK expression, and induce IL-8 and TGF-b1 production (Zhou et al., 2011).

There have been fewer studies of cigarette smoking and risk of CML with some (Kinlen and Rogot, 1988; Kabat et al., 2013; Musselman et al., 2013), but not others (Bjork et al., 2001; Fernberg et al., 2007; Strom et al., 2009; Richardson et al., 2008), finding an association. More recently, investigators examined the relationship of smoking with subtypes of MPN and found an association with polycythemia vera, but not essential thrombocythemia (Leal et al., 2014). Leal and colleagues postulated etiologic differences, with smoking-related carcinogenic pathways linked with polycythemia vera, whereas obesity-related inflammatory pathways (see below) appeared to be more important for essential thrombocythemia. In a population-based case control study of myeloid leukemia, the elevated risk of AML associated with cigarette smoking declined with increasing number of years since quitting, while the risk reduction was more gradual for CML (Musselman et al., 2013).

**<2> DIET**

Overall, there have been a few exploratory studies assessing the possible role of diet in AML and even fewer in MDS and MPN. Two case-control studies (Li et al., 2006; Yamamura et al., 2013) and one cohort study (Ma et al., 2010) found that consumption of beef or meat, in general, increased risk of AML (Li et al., 2006; Ma et al., 2010; Yamamura et al., 2013), but there was no evidence of an association with level of doneness or meat mutagens (Ma et al., 2010). Findings are inconsistent, however, as to whether those who consume high levels of vegetables or fruits experience reduced risks of AML (Ma et al., 2010; Yamamura et al., 2013). Notably, higher dietary intake of isoflavones was associated with reduced risk of MDS in a hospital-based case contol study in China (Liu, 2015).

**<2> ALCOHOL**

Some types of alcoholic drinks contain substances that have anti-carcinogenic properties, particularly polyphenols (Arranz et al., 2012). Studies evaluating alcohol consumption and AML risk have generally not found a relationship (Williams and Horm, 1977; Blackwelder et al., 1980; Hinds et al., 1980; Carstensen et al., 1990), demonstrated a modest inverse association (Brown et al., 1992), or showed divergent results, with reduced risks for light or moderate beer intake and increased risks for moderate to heavy red wine consumption (Rauscher et al., 2004). Hospital-based, case-control studies assessing alcohol consumption and MDS have shown conflicting results (Ido et al., 1996; Liu et al., 2016), while a large cohort study found no association (Ma et al., 2010). A meta-analysis including 745 cases of MDS from five studies found a non-significant increase in MDS (RR = 1.31, 95% CI = 0.79-2.18) with higher versus lower alcohol consumption (Du et al., 2010). No association was observed between alcohol consumption and MPN in two cohort studies of women (Kroll et al., 2012; Leal et al., 2014).

**<2> BODY MASS INDEX (BMI)**

A meta-analysis including seven studies found an association of increasing BMI with increased risk of AML, which was estimated as a 3.1% increase in risk of AML per kg/m2  (Larson and Wolk, 2008). Five studies included in a meta-analysis of CML revealed an increase in relative risk among obese, but not overweight persons, but there was no evidence of a linear trend (Castillo et al., 2012). A large cohort study found increasing risk of MDS with increasing level of BMI (Ma et al., 2009). A case-control study described obesity both in early life and later in life to be strongly associated with risk of AML (Poynter et al., 2016). The Iowa Women’s cohort study found that increased BMI was associated with increased risk of essential thrombocythemia, but not polycythemia vera (Leal et al., 2014). Although the biological mechanism(s) that may be responsible for risk associated with BMI have not been clearly identified, possibilities include alterations in levels of insulin-like growth factor-1 (increased in response to the insulin resistance associated with obesity and demonstrates mitogenic activity in myeloid and lymphoid leukemia cell lines), leptin levels (increased in obesity and affects proliferation and differentiation of myeloid leukemia cell lines), or other hormones (*e.g.,* adiponectin, insulin or sex steroids) or changes in the bone marrow environment (Karmali et al., 2015; Poynter et al., 2016).

**<2> HAIR DYE USE**

Hair dyes, particularly in past decades, contained some carcinogenic chemicals, but the chemical constituents have changed over time (IARC, 2010). Hair dye use, particularly dark hair dyes for longer duration, has been weakly linked with adult AML in a large case-control study (Rauscher et al., 2004), but not in a large cohort study (Altekruse et al., 1999). Most studies have found no relationship for total or specific types of leukemias (Correa et al., 2000; IARC, 2010; Zhang et al., 2012). Weak associations have been reported in some case-control studies of MDS (Ido et al., 1996), CML (Cantor et al., 1988), and essential thrombocythemia (Mele et al., 1996) based on small numbers of exposed cases and limited exposure data.

**<1> INFECTIOUS AGENTS**

Few studies have assessed the potential role of infectious agents in the etiology of myeloid neoplasms, and findings have not been consistent (Doody et al., 1992; Zheng et al., 1993). An intriguing finding was a positive association between early age at onset of childhood viral infections and risk of AML (Cooper et al., 1996). Excess risk of myeloid leukemia has also been reported in patients with acquired immunodeficiency syndrome (AIDS) (Shiels and Engels, 2012), but the reasons are unknown. In a large study in Sweden that linked hospital discharge data with population-based cancer registry data, the investigators found modest 30 percent statistically significant excess risks of adult AML and MDS associated with a history of any prior infectious disease. These findings were based on elevated risks of AML in relation to prior pneumonia, tuberculosis, intestinal infections, septicemia, hepatitis C, pyelonephritis, sinusitis, nasopharyngitis, upper respiratory infections, meningitis, cytomegalovirus, and cellulitis, with individual risk estimates ranging from 1.2-5.6, but the majority <2-fold elevated (Kristinsson et al., 2011). The elevated risks were still apparent when infections occurring less than 3 years before diagnosis were excluded. Increased risk of MDS was associated with prior history of pneumonia and cellulitis, and the elevated risks also were apparent when a latency of 3 or more years was considered. The Swedish linked registry analysis was based on infections treated on an inpatient basis, without specific validation of the diagnoses of infection, and without available treatment data and other potentially confounding information. These associations need to be confirmed in other populations. Given the indolent nature of many MDS cases and the often lengthy period between onset and clinical diagnosis, future studies should consider longer latency periods. Identification and validation of relevant infectious agents in animal and human studies would be helpful, particularly if sufficient numbers of MDS cases could be evaluated in a large cohort pooling project to determine the likelihood that the associations are etiological in nature.

**<1> REPRODUCTIVE FACTORS**

Data are limited and inconsistent on the relationship between exogenous hormone use and myeloid neoplasms. A small population-based case-control study of acute leukemia in the Province of Rome described an increased risk of AML among women who took oral contraceptives based on drugs received through the National Health Service in Italy at least 12 months before diagnosis (Traversa et al., 1998). In contrast, a small case-control study in Minnesota reported a protective effect between longer duration of oral contraceptive use and adult acute leukemia (Poynter et al., 2013). The Minnesota study found little evidence for an association between other reproductive factors or use of hormone replacement therapy and risk of myeloid leukemia overall or, specifically, AML or CML.

**<1> MEDICAL CONDITONS**

**<2> AUTOIMMUNE DISORDERS**

Linkage of medical record or medical insurance information with population-based cancer registry incidence data has been used to assess the relationship between autoimmune disorders and myeloid neoplasms. Among 9,468 AML cases, Kristinsson and colleagues considered 25 autoimmune disorders combined and found 1.7-fold increased risk of AML based on 359 patients with AML and any prior autoimmune disease (Kristinsson et al., 2011). The excess risk was somewhat lower, albeit still significantly 1.4-fold increased, if autoimmune disorders diagnosed within 3 years of diagnosis of AML were excluded. Combining the same 25 autoimmune disorders, Kristinsson and colleagues reported that risk of MDS was increased 2.1-fold based on 133 patients with any autoimmune disorder among 1,662 MDS cases; excluding patients whose autoimmune disorders were diagnosed within 3 years of MDS diagnosis, a lower 1.7-fold excess risk was apparent (Kristinsson et al., 2011). Using a subset of the same Swedish linked registry data, Hemminki and colleagues reported a similar significantly elevated risk of AML associated with a combined grouping of 33 autoimmune diseases (standardized incidence ratio [SIR] = 1.85), and risks of similar magnitude for CML (SIR = 1.68), other myeloid leukemia (SIR = 2.20), but somewhat lower risk for myelofibrosis (SIR = 1.36) (Hemminki et al., 2013). Based on an evaluation of 27 autoimmune diseases and risk of myeloid neoplasms among patients ages 66-99 years old, results from a linkage of the U.S. population-based SEER cancer registries with Medicare data revealed increased risks of AML (OR = 1.29, based on 973 cases with any autoimmune disorder among 7,824 individuals with AML) and MDS (OR = 1.50, based on 574 cases with any autoimmune disorder among 2,471 individuals with MDS) (Anderson et al., 2009). Based on few cases, AML was associated with rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatic, autoimmune hemolytic anemia, systemic vasculitis, ulcerative colitis, and pernicious anemia, while MDS was associated with ulcerative colitis and pernicious anemia. Risks were not increased for CML or MPN. Anderson and colleagues suggested that the associations could be due to medications used to treat the autoimmune disorders (including alkylating agents and azathiaprine), shared genetic predispositions between autoimmune disorders and myeloid neoplasms, or involvement of the bone marrow by the autoimmune disorders (Anderson et al., 2009). Several case-control studies have found inconsistent associations of rheumatoid arthritis and myeloid neoplasms (Severson et al., 1989; Cartwright et al., 1988; Zheng et al., 1993; Cooper et al., 1996).

**<2> ORGAN TRANSPLANT PATIENTS**

Solid organ transplant recipients were found to have significantly elevated risk of all myeloid neoplasms (SIR = 4.6), AML (SIR = 2.7), MDS (SIR = 2.7), CML (SIR = 2.3) and polycythemia vera (SIR = 7.2) (Morton et al., 2014). Risks were highest among the patients who were youngest at the time of transplantation and declined notably with increasing age at transplantation for all disease subtypes. There was some variability in risk by time since transplantation, although the patterns generally were not consistent except for a high rate in the first year for polycythemia vera that the investigators considered to be potentially spurious. Risks varied somewhat by type of organ transplant, with particularly high risk for lung recipients, which was consistent with increased AML and MDS risk associated with use of azathioprine and other antimetabolites (Yenson et al., 2008). However, the relatively small numbers of any given type of transplant and subsequent myeloid neoplasm made it difficult to estimate risks precisely. The finding of increased risks of myeloid neoplasms following organ transplantation, which were similar to the elevated risk of myeloid neoplasms among patients with human immunodeficiency virus (HIV)/AIDS and those with autoimmune diseases, suggest that immune dysfunction may be important in the etiology of myeloid neoplasms. Since use of azathioprine in solid organ recipients has declined over time due to availability of alternate agents, it is possible that risks of myeloid neoplasms may decrease with follow-up of more recent organ recipients.

**<2> ALLERGIC DISORDERS**

Overall, the evidence is weak for a relationship of allergic disorders and myeloid neoplasms. Some (Severson et al., 1989), but not all (Cartwright et al., 1988; Doody et al., 1992; Zheng et al., 1993; Cooper et al., 1996), case-control studies reported a reduced risk of all or specific allergic conditions and AML. A U.S. cohort study found little evidence of a protective effect, but included small numbers of all types of leukemia cases combined (Mills et al., 1992). Another U.S. cohort study described no association of all or specific allergic conditions with myeloid neoplasms (Shadman et al., 2013). A Swedish cohort investigation reported that those with asthma and those with hives had an increased incidence of non-CLL leukemia based on small numbers of exposed cases (Soderberg et al., 2004).

**<1> GENETIC RISK FACTORS**

Diverse lines of evidence provide strong support for a heriTable 38-component in the development of leukemia in general, and CLL in particular, but relatively few specific genes have been identified. Although individuals with a family history of leukemia have an elevated risk of developing leukemia themselves, familial aggregation of CLL is well-known to cluster in families, but familial occurrence of myeloid neoplasms is rare. Stronger evidence for the genetic basis of leukemia derives from studies of patients with rare genetic syndromes, but these cases account for only a small proportion of leukemias. Substantial advances in molecular techniques in the last decade have enabled increasingly broad investigations of the potential role of common genetic variation in leukemogenesis. Such studies hold great promise for further advancing our understanding of genetic susceptibility to leukemia, particularly as they consider specific leukemia subtypes and account for potential interactions of genetic susceptibility with other leukemia risk factors.

**<2> FAMILIAL AGGREGATION AND RARE GENETIC SYNDROMES**

The few studies of familial AML pedigrees, which generally include individuals diagnosed across a broad age range and with different types of MDS/AML, have identified several predisposing rare germline mutations with varying penetrance. The most established of these are in *RUNX1*, *CEBPA*, and *GATA2*, transcription factors that are thought to regulate myeloid differentiation (Owen et al., 2008; Pan et al., 2015; Song et al., 1999; Hahn et al., 2011; Smith et al., 2004; Nickels et al., 2013; Churpek et al., 2013; Babushok et al., 2015). Familial platelet disorder with propensity to develop AML is an autosomal dominant syndrome that occurs due to mutations in *RUNX1* (Mangan and Speck, 2011). Key observations among individuals with this disorder include variable rates of hematologic abnormalities, such as thrombocytopenia and abnormal platelet aggregation, and occurrence of a range of MDS/AML subtypes. Families with *GATA2* mutations also frequently demonstrate hematologic abnormalities including MonoMac syndrome, which is associated with reduced numbers of monocytes, natural killer cells, and B cells and increased risk of infections; and Emberger syndrome, which is characterized by lymphedema. In these patients, risk of MDS/AML is strongly elevated, but penetrance is incomplete. In contrast, nearly all individuals in families with mutations in *CEBPA* eventually develop AML, most commonly AML with minimal maturation or AML with maturation, without preceding hematologic abnormalities.

Because of the rare nature of pure familial MDS/AML pedigrees, insight into the genetic basis of myeloid neoplasms is more likely to derive from studies of individuals with inherited genetic syndromes with diverse associated phenotypes or from investigation of common genetic variants for specific myeloid neoplasms, as discussed further below. However, several new susceptibility genes have been proposed recently based on familial aggregation. *TGM6* was identified as one such AML susceptibility gene based on linkage analysis and next-generation sequencing of a multi-generational family with 11 AML cases inherited in an autosomal dominant fashion, without a clear pattern of preceding hematologic abnormalities (Pan et al., 2015). In another study based on four families, germline duplication of *ATG2B* and *GSKIP* on 14q32.2 was recently reported in association with megakaryopoiesis, with frequent progression to AML but also the occurrence of CMML and CML (Saliba et al., 2015).  That study represents one of the few familial studies of myeloid neoplasms other than MDS/AML. Data from large-scale, multi-generational cancer registries show strong familial aggregation for MPN (Landgren et al., 2008) but not for CML (Bjorkholm et al., 2013), supporting the need for further familial studies of myeloid neoplasms.

A number of rare, inherited genetic syndromes are characterized by elevated risk for developing leukemia, although they have a diverse set of presenting features. The best studied of these are the bone marrow failure syndromes, including Fanconi anemia, dyskeratosis congenita, congenital neutropenia, and Shwachman-Diamond syndrome, which increase risk for both AML and MDS (Rommens et al., 2008; Alter et al., 2010; Babushok et al., 2015). The magnitude of the risks can be difficult to quantify precisely because most studies include small numbers of patients. However, it is clear that risks of MDS/AML are striking in these patients. For example, in a cohort of patients with dyskeratosis congenita, risk for AML was approximately 200-fold increased, and risk for MDS was over 2000-fold increased (Alter et al., 2009). The mechanisms underlying these elevated risks are incompletely understood but are thought to relate to abnormal telomere maintenance, defective DNA repair, and abnormal hematopoietic differentiation and proliferation. Recent progress in understanding the genetic basis of these disorders holds promise for elucidating the mechanisms that confer such striking leukemia risks (Khincha and Savage, 2013). For example, the number of known susceptibility genes for dyskeratosis congenita has moved substantially beyond *TERT* and *TERC* to include a range of other genes (Federman and Sakamoto, 2005; Savage et al., 2008). Other hereditary conditions associated with increased risk of MDS/AML include Li-Fraumeni syndrome, ataxia-telangiectasia, and Bloom syndrome (Varley et al., 1997; Olsen et al., 2001; Arora et al., 2014; Ballinger et al., 2015). Although the precise mechanism of leukemogenesis is not known, it is likely related to underlying defects in genomic instability and DNA repair.

Familial monosomy 7 with inherited partial or complete monosomy 7 (a common cytogenetic abnormality in MDS/AML) is associated with increased risk of developing MDS/AML and is also associated with neurologic abnormalities, such as cerebellar ataxia or atrophy (Gaitonde et al., 2010). As described further in Chapter 59, children with Down syndrome (trisomy 21) also have very high risk of developing AML (Bjørge et al., 2008; Xavier et al., 2010). Whereas the genetic syndromes described above generally increase risk for MDS/AML, neurofibromatosis 1 is associated with elevated risks for juvenile myelomonocytic leukemia (JMML), AML, and CML (Rosenbaum and Wimmer, 2014; Seminog and Goldacre, 2013), and Noonan syndrome is associated with JMML (Strullu et al., 2014). The associations observed with both of these syndromes may be related to *RAS* activation.

Twin studies have provided insight into the genetic basis and natural history of leukemia, most notably demonstrating that concordant occurrences of leukemia in monozygotic twin pairs have a common clonal origin (Greaves et al., 2003; Greaves and Wiemels, 2003). Twins with concordant leukemia most frequently develop ALL (Alpar et al., 2015; Couto et al., 2005), although some cases of AML have been reported (Udayakumar et al., 2014; Ng et al., 1999; Debeljak et al., 2013). However, these studies predominantly reflect childhood rather than adult leukemias.

**<2> COMMON GENETIC VARIATION**

Early studies of common genetic variation in germline DNA and leukemia risk yielded modest insights into leukemogenesis. Most studies focused on genes related to DNA repair, carcinogen metabolism, and folate metabolism because of the importance of ionizing radiation and chemical exposures in the etiology of leukemia (Bolufer et al., 2006; Vijayakrishnan and Houlston, 2010). However, results from these studies were often inconsistent, possibly due to limited statistical power, broad case definitions, and investigation of relatively few genetic variants.

With the advent of microarray technology for identifying large numbers of common genetic variants, agnostic interrogation of susceptibility variants across the entire genome is now possible. Although a number of genome-wide association studies (GWAS) have been performed for childhood ALL (described in Chapter 59), only four GWAS have investigated susceptibility loci for any type of myeloid neoplasm. A study of 671 CML cases of Korean and European descent identified CML susceptibility loci at 6q25.1 and 17p11.1 (Kim et al., 2011). Two GWAS with over 3500 cases of myeloproliferative neoplasms identified a number of susceptibility loci, including 3q26.2, 3p24.2, 5p15.33, 6q23.3, and 9p24.1 (Kilpivaara et al., 2009; Tapper et al., 2015). The associations for some loci differed by *JAK2* mutation status, supporting the importance of uniform case definitions in such studies. Finally, a study of 150 cases of t-AML of European descent identified a locus at 17q12, albeit not at genome-wide significance, that appeared to have a greater effect when the case population was restricted to t-AML cases with abnormalities in chromosomes 5 and/or 7, which is highly correlated with antecedent alkylating agent exposure (Knight et al., 2009). That study supports the intriguing possibility that certain susceptibility variants may only confer risk in the presence of a particular leukemogenic exposure. To maximize the discovery potential for identifying germline susceptibility to myeloid neoplasms, future investigations should account for heterogeneity in both exposures and disease subtypes.

Attention is increasingly turning to the potential role of common genetic variation in relation to therapeutic response and disease prognosis. Results of initial studies that have focused on candidate genes that may confer drug resistance (e.g., drug metabolizing enzymes) have been conflicting and expanded pharmacogenetic studies and GWAS are underway (Drenberg et al., 2015; Choi et al., 2013). For myeloid neoplasms, the investigation of germline variants related to therapeutic response and disease prognosis is in its infancy, in stark contrast to the extensive understanding of the prognostic as well as diagnostic importance of certain somatic changes.

Additional research is needed to understand the mechanisms by which putative loci may contribute to leukemia development or prognosis and to identify other associated genetic loci. Important directions for future research will be to compare risks for different myeloid neoplasms, and to consider whether underlying susceptibility variants may interact with other leukemia risk factors (Knight et al., 2009).

**<1> OPPORTUNITIES FOR PREVENTION**

Advances in molecular biology, genetics, and mechanistic aspects of pathogenesis of myeloid neoplasms have been notable, but progress has been slower in identifying etiologic factors, which limits opportunities for prevention. Nevertheless, efforts should be made to reduce medical, occupational, and environmental exposures to radiation, and balance risks versus benefits of cytotoxic and other medications and chemicals implicated in myeloid neoplasms.

Radiologists, radiologic technologists, medical physicists, and manufacturers of x-ray equipment should continuously seek to optimize diagnostic radiologic procedures to provide clinically important information at the lowest possible doses achievable and to provide estimates of radiation exposure from such procedures to physicians and patients. Reducing radiation exposure from diagnostic procedures is a shared responsibility of the referring medical practitioner and the radiologist, with increasing input from professional societies (e.g., the American College of Radiology) in the form of evidence- and/or consensus-based guidelines produced by panels of experts with respect to the most appropriate examinations or modalities and frequency of examinations recommended for clinical evaluations (American College of Radiology, 2015; Einstein et al., 2014). Unnecessary medical diagnostic radiologic procedures should be avoided. Radiation and medical oncologists should continue to weigh risks of leukemia, second cancers, and other serious adverse sequelae from therapeutic radiation and cytotoxic therapy against the clinical benefits. Newer radiation therapy techniques and modalities have been designed to limit radiation scatter to normal tissue from therapeutic radiation. Research is needed to ascertain whether t-MDS/AML and other second cancer risks are lower with newer radiotherapy techniques or modalities than with conventional radiotherapy. Similarly, research is needed to better understand the risks associated with newer cytotoxic agents and other systemic therapies (e.g., taxanes, immunotherapy).

Radiation workers should utilize all radiation protective safety measures feasible. Medical radiation workers should actively seek maximal use of all personal protective measures (including full coverage lead aprons, thyroid shields, and lead goggles), other protective measures (room shields), maintenance of the longest distance feasible from radiation sources that is still consistent with good patient care, and use of all badge monitoring devices as recommended by radiation safety officers. Radiation safety officers, radiologists, and hospital administration should select x-ray equipment that provides the best visualization for the lowest possible exposures to patients and radiation workers, the greatest flexibility to incorporate adjustments for body size, and meaningful estimates of radiation exposure associated with radiological examinations. Nuclear workers should similarly use all recommended badge monitoring devices, and radiation safety officers should seek to reduce all unnecessary exposures.

Workers in industries that utilize benzene and formaldehyde in manufacturing, transport, or storage and those in the rubber manufacturing industry should regularly employ all personal protective (respirators, clothing, and use of equipment to limit dermal exposures) and workplace safety measures (improve ventilation, minimize levels of relevant chemicals to the lowest achievable levels), wear monitoring devices, participate in formal safety training, and undergo regular evaluation to minimize their exposures to these chemicals. Manufacturers should reduce the amount of benzene in gasoline, paints, solvents, and other sources. Formaldehyde levels should be reduced and alternative less toxic agents should be sought. Although further clarification is needed of the relation between specific pesticides and myeloid neoplasms, protective measures should be utilized in jobs and industries using such agents in an effort to limit exposures.

For the general population, the most important personal measure to reduce risk of myeloid neoplasms is to avoid use of tobacco, and gasoline service stations should continue to upgrade devices to minimize exposure to benzene by those who pump gasoline. Ideally, individuals should consider using vehicles with sources of ‘fuel’that do not contain benzene. While the association of myeloid neoplasm risk with BMI remains to be elucidated, reducing overweight or obesity to normal weight has numerous other health benefits, including prevention of non-hematologic cancers.

**<1> FUTURE DIRECTIONS**

AML has long been reported to population-based cancer registries, but other major categories and subtypes of myeloid neoplasms have not been included until recently in some countries or at all in others. With the rapid evolution of molecular markers, it is important for clinicians to incorporate the most recent guidelines into diagnostic evaluations, both for precision in disease classification and selection of appropriate treatment. Incomplete disease registration or inadequate diagnostic evaluation of myeloid neoplasms in the general population is a major obstacle for characterizing patterns and trends. Efforts are needed worldwide to completely ascertain, correctly diagnose, and employ state-of-the-art molecular characterization of subtypes of AML, MDS, MPN, and MDS/MPN to facilitate progress in identifying etiologic factors, preventive measures, and appropriate therapies.

Epidemiologic studies have focused on AML and, to a lesser extent, on MDS, t-MDS/AML, and CML, but there has been little evaluation of risk factors by subtype of AML, MDS, MPN, or MDS/MPN. Gaps in understanding the pathogenesis of myeloid neoplasms remain, even for well-established risk factors. Epidemiologic studies of radiation and myeloid neoplasms have generally not evaluated subtypes of AML, MDS, MPN, or MDS/MPN. The intriguing association of radiation dose and risk of MDS in the atomic bomb survivors requires further follow-up in that population and comprehensive dose-response assessment in other radiation-exposed populations. The association of low-level benzene exposure with MDS and absence of associations with AML and MPN in the pooled Canadian, U.K., and Australian study should be examined in other populations with varying levels of benzene exposure and in relation to time since first exposure and other temporal characteristics. Incidence of myeloid neoplasms by major category and subtypes should be evaluated in exposed occupational populations in relation to dose response and temporal characteristics. Epidemiologic studies of cytotoxic agents have often focused on a single drug and have not adequately considered joint effects of multiple agents or confounding exposures. Lastly, most studies of well-established risk factors have not assessed genetic or familial factors in these associations.

Promising leads for further study include clarification of the association of myeloid neoplasms with BMI and the intriguing associations with infectious and inflammatory conditions. Although the statistical associations of selected autoimmune conditions and specific myeloid neoplasms have been reproduced in Swedish and U.S. populations, it will be clinically important to clarify whether these associations are related to medications used to treat these conditions, the conditions themselves, and/or genetic characteristics. Further large-scale studies are needed to identify genetic predisposition to myeloid neoplasms, considering both rare, high-penetrant and more common low-risk variants. Such studies should consider both commonalities and differences in genetic susceptibility among the myeloid neoplasms. Intensive efforts are underway to identify host-related genetic variables that influence risk of developing t-AML (Knight et al., 2009).

Few epidemiologic studies to date have been designed specifically to assess risk factors for MPN. Most of the reports on MPN have derived from studies designed to focus on other outcomes or exposures not specifically implicated in occurrence of MPN. Data are limited on identification of determinants of transformation of MDS or MPN to t-AML. Clinically, it would be valuable to clarify what exposures or genetic characteristics facilitate or protect against such transformation. Linked registry studies of transformation of MPN to t-AML have limited information on confounders and have not disentangled main effects under study from known or suspected confounding exposures.

The ultimate goal of epidemiologic research on myeloid neoplasms is to identify risk factors and thereby prevent occurrence of pre-leukemic and leukemic entities. The uncommon incidence of the major categories of myeloid neoplasms, changing classification schemes, and the rarity of subtypes within these major categories complicate efforts to undertake epidemiologic studies. Standard, single center case-control studies have limited power to identify statistical associations that are modest to moderate in level, even if such risk factors (*e.g.*, cigarette smoking, BMI, or diagnostic radiological procedures) involve millions of persons and are of public health importance. Lack of reproducibility of findings and delays between reports from the few existing case-control studies have hampered progress in identifying risk factors. A multi-center, inter-disciplinary approach (e.g., epidemiologists working together with expert clinicians and experienced cancer registry staff) is needed. Strategies might include: (1) establishment of large cohorts of newly diagnosed patients with specific pre-leukemic disorders for long-term follow-up to identify risk factors that increase risk of transformation and identify determinants that prevent transformation through cohort and nested case-cohort studies; (2) identification of cohorts of families with multi-generation occurrence of specific or mixtures of myeloid neoplasms for detailed genetic studies and investigations to assess gene-environment interaction; and, if feasible, (3) large population-based case-control studies of groups of patients with specific pre-leukemic disorders and of myeloid leukemias to evaluate and compare risk factors more generally.

The WHO classification of hematopoietic and lymphoid malignancies has transformed our understanding of pathogenesis, clinical, and prognostic aspects of these disorders and, with continued updates, offers new opportunities for epidemiologic research. Epidemiologic studies of myeloid neoplasms require a shift in standard methods as well as international, multi-disciplinary efforts to clarify risk factor differences and similarities across subtypes and to identify preventive measures.

**<1> ACKNOWLEDGMENTS**

The authors are indebted to Mr. David Check for preparation of figures and Table 38-1 and to Mr. Wayne Liu for technical assistance with manuscript preparation. Support for the work on this project was provided by the Intramural Research Program of the National Institutes of Health, National Cancer Institute and the U.S. Public Health Service of the Department of Health and Human Services.

**<1> REFERENCES**

Anonymous. 1995. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med, 123(9), 656-664. PMID: 7574220.

Abdulkarim K, Girodon F, Johansson P et al. 2009. AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol, 82(2), 106-111. PMID: 19134023.

Ades L, Itzykson R, and Fenaux P. 2014. Myelodysplastic syndromes. Lancet, 383(9936), 2239-2252. PMID: 24656536.

Allemani C, Weir HK, Carreira H et al. 2015. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, 385(9972), 977-1010. PMID: 25467588.

Alpar D, Wren D, Ermini L et al. 2015. Clonal origins of ETV6-RUNX1(+) acute lymphoblastic leukemia: studies in monozygotic twins. Leukemia, 29(4), 839-846. PMID: 25388957.

Altekruse SF, Henley SJ, and Thun MJ. 1999. Deaths from hematopoietic and other cancers in relation to permanent hair dye use in a large prospective study (United States). Cancer Causes Control, 10(6), 617-625. PMID: 10616830.

Alter BP, Giri N, Savage SA et al. 2010. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. British Journal of Haematology, 150(2), 179-188.

Alter BP, Giri N, Savage SA, and Rosenberg PS. 2009. Cancer in dyskeratosis congenita. Blood, 113(26), 6549-6557. PMCID: PMC2710915.

American College of Radiology. 2015. Diagnostic Radiology: Computed Tomography (CT) Practice Parameters and Technical Standards. Available from: http://www.acr.org/quality-safety/standards-guidelines/practice-guidelines-by-modality/ct Accessed on2016.

American College of Radiology. 2015. Radiation Safety. Available from: http://www.acr.org/quality-safety/radiology-safety/radiation-safety Accessed on2016.

Anderson LA, Duncombe AS, Hughes M et al. 2012. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol, 87(2), 175-182. PMID: 22076943.

Anderson LA, Pfeiffer RM, Landgren O et al. 2009. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer, 100(5), 822-828. PMCID: PMC2653768.

Arora H, Chacon AH, Choudhary S et al. 2014. Bloom syndrome. Int J Dermatol, 53(7), 798-802. PMID: 24602044.

Arranz S, Chiva-Blanch G, Valderas-Martinez P et al. 2012. Wine, beer, alcohol and polyphenols on cardiovascular disease and cancer. Nutrients, 4(7), 759-781. PMCID: PMC3407993.

Babushok DV, and Bessler M. 2015. Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol, 28(1), 55-68. PMCID: PMC4323616.

Bachand AM, Mundt KA, Mundt DJ, and Montgomery RR. 2010. Epidemiological studies of formaldehyde exposure and risk of leukemia and nasopharyngeal cancer: a meta-analysis. Crit Rev Toxicol, 40(2), 85-100. PMID: 20085478.

Ballinger ML, Mitchell G, and Thomas DM. 2015. Surveillance recommendations for patients with germline TP53 mutations. Curr Opin Oncol, 27(4), 332-337. PMID: 26049273.

Band PR, Le ND, Fang R et al. 1996. Cohort study of Air Canada pilots: mortality, cancer incidence, and leukemia risk. Am J Epidemiol, 143(2), 137-143. PMID: 8546114.

Barbui T. 2004. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol, 41(2 Suppl 3), 15-17. PMID: 15190518.

Barbui T, Thiele J, Passamonti F et al. 2011. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol, 29(23), 3179-3184. PMID: 21747083.

Beane Freeman LE, Blair A, Lubin JH et al. 2009. Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort. J Natl Cancer Inst, 101(10), 751-761. PMCID: PMC2684555.

Beane Freeman LE, Bonner MR, Blair A et al. 2005. Cancer incidence among male pesticide applicators in the Agricultural Health Study cohort exposed to diazinon. Am J Epidemiol, 162(11), 1070-1079. PMID: 16236997.

Bennett JM. 2000. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol, 72(2), 131-133. PMID: 11039659.

Bennett JM. 2013. The myelodysplastic syndromes: a personal recollection of four decades of classification and prognostic scoring systems. Leuk Lymphoma, 54(12), 2588-2591. PMID: 23547832.

Bennett JM, Catovsky D, Daniel MT et al. 1994. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol, 87(4), 746-754. PMID: 7986717.

Bennett JM, Catovsky D, Daniel MT et al. 1976. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol, 33(4), 451-458. PMID: 188440.

Bennett JM, Catovsky D, Daniel MT et al. 1989. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol, 42(6), 567-584. PMCID: PMC1141984.

Bernard MP, Bancos S, Sime PJ, and Phipps RP. 2008. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des, 14(21), 2051-2060. PMCID: PMC2745246.

Bhatia S. 2013. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol, 40(6), 666-675. PMCID: PMC3867743.

Bjørge T, Cnattingius S, Lie RT, Tretli S, and Engeland A. 2008. Cancer risk in children with birth defects and in their families: A population based cohort study of 5.2 million children from Norway and Sweden. Cancer Epidemiology Biomarkers & Prevention, 17(3), 500-506.

Bjork J, Albin M, Welinder H et al. 2001. Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occup Environ Med, 58(11), 722-727. PMCID: PMC1740065.

Bjorkholm M, Derolf AR, Hultcrantz M et al. 2011. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol, 29(17), 2410-2415. PMCID: PMC3107755.

Bjorkholm M, Kristinsson SY, Landgren O, and Goldin LR. 2013. No familial aggregation in chronic myeloid leukemia. Blood, 122(3), 460-461. PMCID: PMC3716206.

Blackwelder WC, Yano K, Rhoads GG et al. 1980. Alcohol and mortality: the Honolulu Heart Study. Am J Med, 68(2), 164-169. PMID: 7355889.

Blair A, and Zahm SH. 1995. Agricultural exposures and cancer. Environ Health Perspect, 103 Suppl 8, 205-208. PMCID: PMC1518967.

Bochtler T, Frohling S, and Kramer A. 2015. Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. Leukemia, 29(6), 1243-1252. PMID: 25673237.

Boice JD, Jr. 2006. Ionizing radiation. In: Schottenfeld D, and Fraumeni J F (Eds.), Cancer Epidemiology and Prevention (3rd ed., pp. 259-293). New York: Oxford University.

Boice JD, Jr., Blettner M, Kleinerman RA et al. 1987. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst, 79(6), 1295-1311. PMID: 3480381.

Boice JD, Jr., Morin MM, Glass AG et al. 1991. Diagnostic x-ray procedures and risk of leukemia, lymphoma, and multiple myeloma. JAMA, 265(10), 1290-1294. PMID: 2053936.

Bolufer P, Barragan E, Collado M et al. 2006. Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res, 30(12), 1471-1491.

Borthakur, G., Lin, E., Jain, N., Estey, E.E., Cortes, J.E., O'Brien, S., Faderl, S., Ravandi, F., Pierce, S. & Kantarjian, H. (2009) Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer, 115, 3217-3221.

Brown LM, Gibson R, Burmeister LF et al. 1992. Alcohol consumption and risk of leukemia, non-Hodgkin's lymphoma, and multiple myeloma. Leuk Res, 16(10), 979-984. PMID: 1405712.

Caldwell GG, Kelley DB, and Heath CW, Jr. 1980. Leukemia among participants in military maneuvers at a nuclear bomb test. A preliminary report. JAMA, 244(14), 1575-1578. PMID: 6932516.

Campbell PJ, and Green AR. 2006. The myeloproliferative disorders. N Engl J Med, 355(23), 2452-2466. PMID: 17151367.

Cancer Genome Atlas Research Network. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368(22), 2059-2074. PMID: 23634996.

Candelaria M, and Duenas-Gonzalez A. 2015. Therapy-related myelodysplastic syndrome. Expert Opin Drug Saf, 14(5), 655-665. PMID: 25675961.

Cantor KP, Blair A, Everett G et al. 1988. Hair dye use and risk of leukemia and lymphoma. Am J Public Health, 78(5), 570-571. PMCID: PMC1349342.

Cardis E, Vrijheid M, Blettner M et al. 2005. Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries. BMJ, 331(7508), 77. PMCID: PMC558612.

Carstensen JM, Bygren LO, and Hatschek T. 1990. Cancer incidence among Swedish brewery workers. Int J Cancer, 45(3), 393-396. PMID: 2407667.

Cartwright RA, Darwin C, McKinney PA et al. 1988. Acute myeloid leukemia in adults: a case-control study in Yorkshire. Leukemia, 2(10), 687-690. PMID: 3172845.

Castillo JJ, Reagan JL, Ingham RR et al. 2012. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res, 36(7), 868-875. PMID: 22285508.

CDC. Surgeon General's Report. 2010. Chemicals in Tobacco.

Chabner B, Bertino J, Cleary J et al. 2011. Cytotoxic Agents. In: Brunton L, Chabner B, and Knollmann B (Eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics (12 ed.). New York, NY: McGraw-Hill.

Choi H, Jung C, Sohn SK et al. 2013. Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype. Br J Haematol, 163(1), 62-71. PMID: 24159609.

Churpek JE, Lorenz R, Nedumgottil S et al. 2013. Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma, 54(1), 28-35. PMID: 22691122.

Cogle CR. 2015. Incidence and Burden of the Myelodysplastic Syndromes. Curr Hematol Malig Rep, 10(3), 272-281. PMID: 26134527.

Cohen T, and Creger WP. 1967. Acute myeloid leukemia following seven years of aplastic anemia induced by chloramphenicol. Am J Med, 43(5), 762-770. PMID: 5234001.

Cooper GS, Kamel F, Sandler DP, Davey FR, and Bloomfield CD. 1996. Risk of adult acute leukemia in relation to prior immune-related conditions. Cancer Epidemiol Biomarkers Prev, 5(11), 867-872. PMID: 8922293.

Correa A, Mohan A, Jackson L, Perry H, and Helzlsouer K. 2000. Use of hair dyes, hematopoietic neoplasms, and lymphomas: a literature review. I. Leukemias and myelodysplastic syndromes. Cancer Invest, 18(4), 366-380. PMID: 10808373.

Couto E, Chen B, and Hemminki K. 2005. Association of childhood acute lymphoblastic leukaemia with cancers in family members. British Journal of Cancer, 93(11), 1307-1309.

Cowell IG, Sondka Z, Smith K et al. 2012. Model for MLL translocations in therapy-related leukemia involving topoisomerase IIbeta-mediated DNA strand breaks and gene proximity. Proc Natl Acad Sci U S A, 109(23), 8989-8994. PMCID: PMC3384169.

Craig BM, Rollison DE, List AF, and Cogle CR. 2012. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomarkers Prev, 21(3), 474-481. PMCID: 3662977.

Dameshek W. 1951. Some speculations on the myeloproliferative syndromes. Blood, 6(4), 372-375. PMID: 14820991.

Daniels RD, and Schubauer-Berigan MK. 2011. A meta-analysis of leukaemia risk from protracted exposure to low-dose gamma radiation. Occup Environ Med, 68(6), 457-464. PMCID: PMC3095477.

Darby SC, Whitley E, Howe GR et al. 1995. Radon and cancers other than lung cancer in underground miners: a collaborative analysis of 11 studies. J Natl Cancer Inst, 87(5), 378-384. PMID: 7853419.

Debeljak M, Kitanovski L, Pajic T, and Jazbec J. 2013. Concordant acute myeloblastic leukemia in monozygotic twins with germline and shared somatic mutations in the gene for CCAAT-enhancer-binding protein alpha with 13 years difference at onset. Haematologica, 98(7), e73-74. PMCID: PMC3696596.

Delzell E, Sathiakumar N, Graff J, Macaluso M, Maldonado G, Matthews R. Health Effects Institute. 2006; Res Rep Health Eff Inst, 132, 1-63. (Wayne – this one won’t be in Pub Med)

Dohner H, Weisdorf DJ, and Bloomfield CD. 2015. Acute Myeloid Leukemia. N Engl J Med, 373(12), 1136-1152. PMID: 26376137.

Doody MM, Linet MS, Glass AG et al. 1996. Risks of non-Hodgkin's lymphoma, multiple myeloma, and leukemia associated with common medications. Epidemiology, 7(2), 131-139. PMID: 8834551.

Doody MM, Linet MS, Glass AG et al. 1992. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control, 3(5), 449-456. PMID: 1525326.

Dores GM, Devesa SS, Curtis RE, Linet MS, and Morton LM. 2012. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood, 119(1), 34-43. PMID: 22086414.

Drenberg CD, Paugh SW, Pounds SB et al. 2015. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther. PMID: 26663398.

Du Y, Fryzek J, Sekeres MA, and Taioli E. 2010. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk Res, 34(1), 1-5. PMID: 19747728.

Einstein AJ, Berman DS, Min JK et al. 2014. Patient-centered imaging: shared decision making for cardiac imaging procedures with exposure to ionizing radiation. J Am Coll Cardiol, 63(15), 1480-1489. PMCID: PMC3994983.

Elliott P, Shaddick G, Douglass M et al. 2013. Adult cancers near high-voltage overhead power lines. Epidemiology, 24(2), 184-190. PMID: 23337237.

Evans DG, Birch JM, Ramsden RT, Sharif S, and Baser ME. 2006. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet, 43(4), 289-294. PMCID: PMC2563223.

Federman N, and Sakamoto KM. 2005. The genetic basis of bone marrow failure syndromes in children. Mol Genet Metab, 86(1-2), 100-109.

Ferlay J, Soerjomataram I, Ervik M et al. 2014. Cancer Incidence and Mortality Worldwide. Available from: http://www.wcrf.org/int/cancer-facts-figures/worldwide-data Accessed on Feb 29, 2016.

Fernberg P, Odenbro A, Bellocco R et al. 2007. Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. Cancer Res, 67(12), 5983-5986. PMID: 17575169.

Ferrara F, and Schiffer CA. 2013. Acute myeloid leukaemia in adults. Lancet, 381(9865), 484-495. PMID: 23399072.

Feychting M, and Ahlbom A. 1994. Magnetic fields, leukemia, and central nervous system tumors in Swedish adults residing near high-voltage power lines. Epidemiology, 5(5), 501-509. PMID: 7986864.

Fircanis S, Merriam P, Khan N, and Castillo JJ. 2014. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol, 89(8), E125-132. PMID: 24753145.

Fleenor CJ, Higa K, Weil MM, and DeGregori J. 2015. Evolved Cellular Mechanisms to Respond to Genotoxic Insults: Implications for Radiation-Induced Hematologic Malignancies. Radiat Res, 184(4), 341-351. PMCID: PMC4617554.

Fraumeni JF, Jr. 1967. Bone marrow depression induced by chloramphenicol or phenylbutazone. Leukemia and other sequelae. JAMA, 201(11), 828-834. PMID: 6071896.

Friedman GD. 1982. Phenylbutazone, musculoskeletal disease, and leukemia. J Chronic Dis, 35(4), 233-243. PMID: 7037810.

Fritz A, Percy C, Jack A et al (Eds.). 2000. International Classification of Diseases for Oncology (3rd ed.). Geneva, Switzerland: World Health Organization.

Gaitonde S, Boumendjel R, Angeles R, and Rondelli D. 2010. Familial childhood monosomy 7 and associated myelodysplasia. J Pediatr Hematol Oncol, 32(6), e236-237. PMID: 20661156.

Gangatharan SA, Grove CS, P'ng S et al. 2013. Acute myeloid leukaemia in Western Australia 1991-2005: a retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome. Intern Med J, 43(8), 903-911. PMID: 23611681.

Glass DC, Schnatter AR, Tang G, Irons RD, and Rushton L. 2014. Risk of myeloproliferative disease and chronic myeloid leukaemia following exposure to low-level benzene in a nested case-control study of petroleum workers. Occup Environ Med, 71(4), 266-274. PMID: 24532441.

Gluzman DF, Sklyarenko LM, Koval SV et al. 2015. Myelodysplastic syndromes in Chernobyl clean-up workers. Ann Hematol, 94(10), 1639-1643. PMID: 26208666.

Godley LA, and Larson RA. 2008. Therapy-related myeloid leukemia. Semin Oncol, 35(4), 418-429. PMCID: PMC2600445.

Goldberg SL, Chen E, Corral M et al. 2010. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol, 28(17), 2847-2852. PMID: 20421543.

Granfeldt Ostgard, L.S., Medeiros, B.C., Sengelov, H., Norgaard, M., Andersen, M.K., Dufva, I.H., Friis, L.S., Kjeldsen, E., Marcher, C.W., Preiss, B., Severinsen, M. & Norgaard, J.M. (2015) Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. J Clin Oncol, 33, 3641-3649.

Greaves MF, Maia AT, Wiemels JL, and Ford AM. 2003. Leukemia in twins: lessons in natural history. Blood, 102(7), 2321-2333. PMID: 12791663.

Greaves MF, and Wiemels J. 2003. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer, 3(9), 639-649. PMID: 12951583.

Greenberg P, Cox C, LeBeau MM et al. 1997. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89(6), 2079-2088. PMID: 9058730.

Greenberg PL, Tuechler H, Schanz J et al. 2012. Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120(12), 2454-2465. PMID: 22740453.

Griem ML, Kleinerman RA, Boice JD, Jr. et al. 1994. Cancer following radiotherapy for peptic ulcer. J Natl Cancer Inst, 86(11), 842-849. PMID: 8182765.

Grimwade D. 2001. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol, 14(3), 497-529. PMID: 11640867.

Grimwade D, Hills RK, Moorman AV et al. 2010. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116(3), 354-365. PMID: 20385793.

Groves FD, Page WF, Gridley G et al. 2002. Cancer in Korean war navy technicians: mortality survey after 40 years. Am J Epidemiol, 155(9), 810-818. PMID: 11978584.

Gundestrup M, and Storm HH. 1999. Radiation-induced acute myeloid leukaemia and other cancers in commercial jet cockpit crew: a population-based cohort study. Lancet, 354(9195), 2029-2031. PMID: 10636367.

Hahn CN, Chong CE, Carmichael CL et al. 2011. HeriTable 38-GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet, 43(10), 1012-1017. PMCID: PMC3184204.

Hammer GP, Auvinen A, De Stavola BL et al. 2014. Mortality from cancer and other causes in commercial airline crews: a joint analysis of cohorts from 10 countries. Occup Environ Med, 71(5), 313-322. PMID: 24389960.

Harada H, Harada Y, Tanaka H, Kimura A, and Inaba T. 2003. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood, 101(2), 673-680. PMID: 12393679.

Hauptmann M, Lubin JH, Stewart PA, Hayes RB, and Blair A. 2003. Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries. J Natl Cancer Inst, 95(21), 1615-1623. PMID: 14600094.

Hauptmann M, Stewart PA, Lubin JH et al. 2009. Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde. J Natl Cancer Inst, 101(24), 1696-1708. PMCID: PMC2794303.

Hayes RB, Yin SN, Dosemeci M et al. 1997. Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine--National Cancer Institute Benzene Study Group. J Natl Cancer Inst, 89(14), 1065-1071. PMID: 9230889.

Hemminki K, Liu X, Forsti A et al. 2013. Subsequent leukaemia in autoimmune disease patients. Br J Haematol, 161(5), 677-687. PMID: 23565673.

Henshaw DL, Eatough JP, and Richardson RB. 1990. Radon as a causative factor in induction of myeloid leukaemia and other cancers. Lancet, 335(8696), 1008-1012. PMID: 1970069.

Hinds MW, Kolonel LN, Lee J, and Hirohata T. 1980. Associations between cancer incidence and alcohol/cigarette consumption among five ethnic groups in Hawaii. Br J Cancer, 41(6), 929-940. PMCID: PMC2010370.

Hoffman R, Benz EJ, Jr., Silberstein LE et al. 2013. Hematology: Basic Principles and Practice. 6th ed. Philadelphia: Saunders/Elsevier.

Howard R, Gilbert E, Lynch CF et al. 2008. Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients. Ann Epidemiol, 18(5), 416-421. PMCID: PMC4034178.

Hsu WL, Preston DL, Soda M et al. 2013. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res, 179(3), 361-382. PMCID: PMC3875218.

IARC. 2001. Ionizing radiation, part 2: some internally deposited radionuclides. IARC Monogr Eval Carcinog Risks Hum, 78, 595.

IARC. 2008. 1,3-butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide). IARC Monogr Eval Carcinog Risks Hum, 97, 510.

IARC. 2010. Some aromatic amines, organic dyes and related exposures. IARC Monogr Eval Carcinog Risks Hum, 99. Personal use of hair dyes pgs 558-658. Lyon, France: IARC.

IARC. 2012. Chemical and related occupations. IARC Monogr Eval Carcinog Risks Hum 100 (Pt F). Benzene pgs 249-294. Butadiene pgs 309-338. Dioxins and related pgs 339-378. Formaldehyde pgs 401-435. Occupational exposure in the rubber manufacturing industry pgs 541-562. Lyon, France: IARC.

IARC. 2013. Non-ionizing radiation, part 2: radiofrequency electromagnetic fields. IARC Monogr Eval Carcinog Risks Hum, 102, 460.

Ido M, Nagata C, Kawakami N et al. 1996. A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res, 20(9), 727-731. PMID: 8947581.

Inaba H, Greaves M, and Mullighan CG. 2013. Acute lymphoblastic leukaemia. Lancet, 381(9881), 1943-1955. PMCID: PMC3816716.

IOM (Institute of Medicine). 2000. The Five Series Study: Mortality of Military Participants in U.S. Nuclear Weapons Tests. Washington, DC: National Academy Press.

Iwanaga M, Hsu WL, Soda M et al. 2011. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol, 29(4), 428-434. PMID: 21149671.

Jablon S, Hrubec Z, and Boice JD, Jr. 1991. Cancer in populations living near nuclear facilities. A survey of mortality nationwide and incidence in two states. JAMA, 265(11), 1403-1408. PMID: 1999880.

Jaffe ES, Harris NL, Stein H, and Vardiman JW (Eds.). 2001. World Health Organization classification of tumours. Pathology and genetics of haematopoietic and lymphoid tissues. Lyon: IARC Press.

James C, Ugo V, Le Couedic JP et al. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434(7037), 1144-1148. PMID: 15793561.

Johansen C, Raaschou Nielsen O, Olsen JH, and Schuz J. 2007. Risk for leukaemia and brain and breast cancer among Danish utility workers: a second follow-up. Occup Environ Med, 64(11), 782-784. PMCID: PMC2078420.

Kabat GC, Wu JW, Moore SC et al. 2013. Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP Diet and Health Study. Cancer Epidemiol Biomarkers Prev, 22(5), 848-854. PMCID: PMC3849026.

Kadia TM, Ravandi F, Cortes J, and Kantarjian H. 2015. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. JAMA Oncol, 1(6), 820-828. PMID: 26181162.

Karmali R, Dalovisio A, Borgia JA et al. 2015. All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies. Blood Rev, 29(2), 71-80. PMID: 25433571.

Karran P. 2006. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull, 79-80, 153-170. PMID: 17277075.

Kasum CM, Blair CK, Folsom AR, Ross JA. 2003. Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol Biomark Prev, 12, 534-7.

Kaye FJ. 2009. Mutation-associated fusion cancer genes in solid tumors. Mol Cancer Ther, 8(6), 1399-1408. PMID: 19509239.

Khalade A, Jaakkola MS, Pukkala E, and Jaakkola JJ. 2010. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Environ Health, 9, 31. PMCID: PMC2903550.

Kheifets L, Monroe J, Vergara X, Mezei G, and Afifi AA. 2008. Occupational electromagnetic fields and leukemia and brain cancer: an update to two meta-analyses. J Occup Environ Med, 50(6), 677-688. PMID: 18545095.

Kheifets LI, Afifi AA, Buffler PA, Zhang ZW, and Matkin CC. 1997. Occupational electric and magnetic field exposure and leukemia. A meta-analysis. J Occup Environ Med, 39(11), 1074-1091. PMID: 9383718.

Khincha PP, and Savage SA. 2013. Genomic characterization of the inherited bone marrow failure syndromes. Semin Hematol, 50(4), 333-347. PMCID: PMC3835370.

Kilpivaara O, Mukherjee S, Schram AM et al. 2009. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet, 41(4), 455-459. PMCID: PMC3676425.

Kim DH, Lee ST, Won HH et al. 2011. A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood, 117(25), 6906-6911. PMID: 21540461.

Kinlen LJ, and Rogot E. 1988. Leukaemia and smoking habits among United States veterans. BMJ, 297(6649), 657-659. PMCID: PMC1834341.

Kipps TJ, and Huan-You W. 2015. Classification of malignant lymphoid disorders Williams Hematatology (8th ed.).

Knight JA, Skol AD, Shinde A et al. 2009. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood, 113(22), 5575-5582. PMCID: PMC2689055.

Koeman T, van den Brandt PA, Slottje P et al. 2014. Occupational extremely low-frequency magnetic field exposure and selected cancer outcomes in a prospective Dutch cohort. Cancer Causes Control, 25(2), 203-214. PMID: 24241907.

Kralovics R, Passamonti F, Buser AS et al. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 352(17), 1779-1790. PMID: 15858187.

Krestinina L, Preston DL, Davis FG et al. 2010. Leukemia incidence among people exposed to chronic radiation from the contaminated Techa River, 1953-2005. Radiat Environ Biophys, 49(2), 195-201. PMID: 20012750.

Kristinsson SY, Bjorkholm M, Hultcrantz M et al. 2011. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol, 29(21), 2897-2903. PMCID: PMC3138717.

Kroll ME, Murphy F, Pirie K et al. 2012. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. Br J Cancer, 107(5), 879-887. PMCID: PMC3425977.

Lan Q, Zhang L, Li G et al. 2004. Hematotoxicity in workers exposed to low levels of benzene. Science, 306(5702), 1774-1776. PMCID: PMC1256034.

Landgren O, Goldin LR, Kristinsson SY et al. 2008. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood, 112(6), 2199-2204. PMCID: PMC2532797.

Larsson SC, Wolk A. 2008. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer, 122, 1418-21.

Laurier D, Jacob S, Bernier MO et al. 2008. Epidemiological studies of leukaemia in children and young adults around nuclear facilities: a critical review. Radiat Prot Dosimetry, 132(2), 182-190. PMID: 18922823.

Laurier D, Valenty M, and Tirmarche M. 2001. Radon exposure and the risk of leukemia: a review of epidemiological studies. Health Phys, 81(3), 272-288. PMID: 11513461.

Leal AD, Thompson CA, Wang AH et al. 2014. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. Int J Cancer, 134(7), 1741-1750. PMCID: PMC3947165.

Lee WJ, Hoppin JA, Blair A et al. 2004. Cancer incidence among pesticide applicators exposed to alachlor in the Agricultural Health Study. Am J Epidemiol, 159(4), 373-380. PMID: 14769641.

Lehmann S, Ravn A, Carlsson L et al. 2011. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia, 25(7), 1128-1134. PMID: 21502956.

Leone G, Fianchi L, Pagano L, and Voso MT. 2010. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact, 184(1-2), 39-45. PMID: 20026017.

Leuraud K, Richardson DB, Cardis E et al. 2015. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. Lancet Haematol, 2(7), e276-e281. PMCID: PMC4587986.

Li Y, Moysich KB, Baer MR et al. 2006. Intakes of selected food groups and beverages and adult acute myeloid leukemia. Leuk Res, 30(12), 1507-1515. PMID: 16678899.

Lichtman MA. 2015. Classification and clinical manifestations of the clonal myeloid disorders Willliams Hematology (8th ed.).

Linet MS. 1985. The Leukemias: Epidemiological Aspects. New York: Oxford University Press.

Linet MS, and Cartwright RA. 1988. Chronic lymphocytic leukemia: epidemiology and etiologic findings. Nouv Rev Fr Hematol, 30(5-6), 353-357. PMID: 3222144.

Linet MS, Devesa SS, and Morgan GJ. 2006. The Leukemias. In: Schottenfeld D, and Fraumeni J F (Eds.), Cancer Epidemiology and Prevention (3rd ed., pp. 841-871). New York: Oxford University Press.

Linet MS, Kim KP, Miller DL et al. 2010. Historical review of occupational exposures and cancer risks in medical radiation workers. Radiat Res, 174(6), 793-808. PMCID: PMC4098897.

Linet MS, Slovis TL, Miller DL et al. 2012. Cancer risks associated with external radiation from diagnostic imaging procedures. CA Cancer J Clin, 62(2), 75-100. PMCID: PMC3548988.

Linet MS, Yin SN, Gilbert ES et al. 2015. A retrospective cohort study of cause-specific mortality and incidence of hematopoietic malignancies in Chinese benzene-exposed workers. Int J Cancer, 137(9), 2184-2197. PMID: 25944549.

Liu P, Holman CD, Jin J, and Zhang M. 2015. Dietary isoflavone intake is associated with a reduced risk of myelodysplastic syndromes. Br J Nutr, 114(12), 2110-2115. PMID: 26458988.

Liu P, Holman CD, Jin J, and Zhang M. 2016. Alcohol consumption and risk of myelodysplastic syndromes: a case-control study. Cancer Causes Control, 27(2), 209-216. PMID: 26590915.

Ludwig A, Jochmann N, Kertesz A et al. 2010. Smoking decreases the level of circulating CD34+ progenitor cells in young healthy women--a pilot study. BMC Womens Health, 10, 20. PMCID: PMC2891626.

Ma X, Lim U, Park Y et al. 2009. Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am J Epidemiol, 169(12), 1492-1499. PMCID: PMC2727203.

Ma X, Park Y, Mayne ST et al. 2010. Diet, lifestyle, and acute myeloid leukemia in the NIH-AARP cohort. Am J Epidemiol, 171(3), 312-322. PMCID: PMC2842202.

Mabuchi K, Fugiwara S, Preston DL, Nakamura N, and Shore RE. 2011. Atomic bomb survivors: long-term health effects of radiation. In: Shrieve D S, and Loeffler J S (Eds.), Human Radiation Injury. Philadelphia: Wolters Kuwer/Lippincott Williams and Wilkins.

Mahajan R, Blair A, Lynch CF et al. 2006. Fonofos exposure and cancer incidence in the agricultural health study. Environ Health Perspect, 114(12), 1838-1842. PMCID: PMC1764168.

Mangan JK, and Speck NA. 2011. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog, 16(1-2), 77-91. PMCID: PMC3248792.

March HC. 1950. Leukemia in radiologists in a 20 year period. Am J Med Sci, 220(3), 282-286. PMID: 14771053.

Matsuo T, Tomonaga M, Bennett JM et al. 1988. Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol, 18(2), 91-96. PMID: 2898029.

Maynadie M, Girodon F, Manivet-Janoray I et al. 2011. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). Haematologica, 96(1), 55-61. PMID: 20971817.

Mc Laughlin J. 2012. An historical overview of radon and its progeny: applications and health effects. Radiat Prot Dosimetry, 152(1-3), 2-8. PMID: 22914338.

McHale CM, Zhang L, and Smith MT. 2012. Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment. Carcinogenesis, 33(2), 240-252. PMCID: PMC3271273.

McKenna RW. 2000. Multifaceted approach to the diagnosis and classification of acute leukemias. Clin Chem, 46(8 Pt 2), 1252-1259. PMID: 10926919.

McKeown SR, Hatfield P, Prestwich RJ, Shaffer RE, and Taylor RE. 2015. Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol, 88(1056), 20150405. PMID: 26462717.

McNally RJ, Roman E, and Cartwright RA. 1999. Leukemias and lymphomas: time trends in the UK, 1984-93. Cancer Causes Control, 10(1), 35-42. PMID: 10334640.

McQuilten ZK, Wood EM, Polizzotto MN et al. 2014. Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. Cancer, 120(11), 1686-1694. PMID: 24643720.

Mele A, Visani G, Pulsoni A et al. 1996. Risk factors for essential thrombocythemia: A case-control study. Italian Leukemia Study Group. Cancer, 77(10), 2157-2161. PMID: 8640685.

Melo JV, and Barnes DJ. 2007. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer, 7(6), 441-453. PMID: 17522713.

Mesa RA, Li CY, Ketterling RP et al. 2005. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood, 105(3), 973-977. PMID: 15388582.

Mesa RA, Loegering D, Powell HL et al. 2005. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood, 106(1), 318-327. PMCID: PMC1895127.

Metayer C, Curtis RE, Vose J et al. 2003. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood, 101(5), 2015-2023. PMID: 12393427.

Mettler FA Jr., Huda W, Yoshizumi TT, Mahesh M. 2008. Effective doses in radiology and diagnostic nuclear medicine: A catalog. *Radiology*, **248**, 254-64.

Meyer SC, and Levine RL. 2014. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol, 15(9), e382-394. PMID: 25079101.

Mills PK, Beeson WL, Fraser GE, and Phillips RL. 1992. Allergy and cancer: organ site-specific results from the Adventist Health Study. Am J Epidemiol, 136(3), 287-295. PMID: 1415150.

Morton LM, Dores GM, Tucker MA et al. 2013. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood, 121(15), 2996-3004. PMCID: PMC3624944.

Morton LM, Gibson TM, Clarke CA et al. 2014. Risk of myeloid neoplasms after solid organ transplantation. Leukemia, 28(12), 2317-2323. PMCID: PMC4197126.

Muirhead CR, Bingham D, Haylock RG et al. 2003. Follow up of mortality and incidence of cancer 1952-98 in men from the UK who participated in the UK's atmospheric nuclear weapon tests and experimental programmes. Occup Environ Med, 60(3), 165-172. PMCID: PMC1740497.

Muirhead CR, O'Hagan JA, Haylock RG et al. 2009. Mortality and cancer incidence following occupational radiation exposure: third analysis of the National Registry for Radiation Workers. Br J Cancer, 100(1), 206-212. PMCID: PMC2634664.

Musselman JR, Blair CK, Cerhan JR et al. 2013. Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol, 37(4), 410-416. PMCID: PMC3819424.

Nardi V, Winkfield KM, Ok CY et al. 2012. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol, 30(19), 2340-2347. PMID: 22585703.

NCRP (National Council on Radiation Protection and Measurements). 2009. Ionizing radiation exposure of the population of the United States. Bethesda, MD: NCRP.

NCRP (National Council on Radiation Protection and Measurements). 2011. Second primary cancers and cardiovascular disease after radiation therapy. Bethesda, MD: NCRP.

Ng KC, Tan AM, Chong YY, Lau LC, and Lou J. 1999. Congenital acute megakaryoblastic leukemia (M7) with chromosomal t(1;22)(p13;q13) translocation in a set of identical twins. J Pediatr Hematol Oncol, 21(5), 428-430. PMID: 10524459.

Nickels EM, Soodalter J, Churpek JE, and Godley LA. 2013. Recognizing familial myeloid leukemia in adults. Ther Adv Hematol, 4(4), 254-269. PMCID: PMC3734901.

Nitiss JL. 2009. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer, 9(5), 338-350. PMCID: PMC2748742.

NRC (National Research Council). 2006. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: National Academy of Sciences.

Olsen JH, Hahnemann JM, Borresen-Dale AL et al. 2001. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. Journal of the National Cancer Institute, 93(2), 121-127. PMID: 11208881.

Owen C, Barnett M, and Fitzgibbon J. 2008. Familial myelodysplasia and acute myeloid leukaemia--a review. British Journal of Haematology, 140(2), 123-132. PMID: 18173751.

Pan LL, Huang YM, Wang M et al. 2015. Positional cloning and next-generation sequencing identified a TGM6 mutation in a large Chinese pedigree with acute myeloid leukaemia. Eur J Hum Genet, 23(2), 218-223. PMCID: PMC4297898.

Park JH, Qiao B, Panageas KS et al. 2011. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, 118(5), 1248-1254. PMID: 21653939.

Passamonti F, Rumi E, Arcaini L et al. 2008. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica, 93(11), 1645-1651. PMID: 18790799.

Passamonti F, Rumi E, Pungolino E et al. 2004. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med, 117(10), 755-761. PMID: 15541325.

Patel JP, Gonen M, Figueroa ME et al. 2012. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med, 366(12), 1079-1089. PMID: 22417203.

Pesatori AC, Consonni D, Tironi A et al. 1993. Cancer in a young population in a dioxin-contaminated area. Int J Epidemiol, 22(6), 1010-1013. PMID: 8144281.

Pogoda JM, Katz J, McKean-Cowdin R et al. 2005. Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: results from a Los Angeles County case-control study. Int J Cancer, 114(4), 634-638. PMID: 15609330.

Pogoda JM, Nichols PW, Ross RK et al. 2011. Diagnostic radiography and adult acute myeloid leukaemia: an interview and medical chart review study. Br J Cancer, 104(9), 1482-1486. PMCID: PMC3101931.

Polednak AP. 2011. US death rates from myeloproliferative neoplasms, and implications for cancer surveillance. J Registry Manag, 38(2), 87-92. PMID: 22096879.

Polednak AP. 2013. Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance. Cancer Epidemiol, 37(5), 569-574. PMID: 23773300.

Polychronakis I, Dounias G, Makropoulos V, Riza E, and Linos A. 2013. Work-related leukemia: a systematic review. J Occup Med Toxicol, 8(1), 14. PMCID: PMC3668148.

Poynter JN, Fonstad R, Blair CK et al. 2013. Exogenous hormone use, reproductive history and risk of adult myeloid leukaemia. Br J Cancer, 109(7), 1895-1898. PMCID: PMC3790163.

Poynter JN, Richardson M, Blair CK et al. 2016. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. Cancer Epidemiol, 40, 134-140. PMCID: PMC4738058.

Preston-Martin S, and Pogoda JM. 2003. Estimation of radiographic doses in a case-control study of acute myelogenous leukemia. Health Phys, 84(2), 245-259. PMID: 12553655.

Preston-Martin S, Thomas DC, Yu MC, and Henderson BE. 1989. Diagnostic radiography as a risk factor for chronic myeloid and monocytic leukaemia (CML). Br J Cancer, 59(4), 639-644. PMCID: PMC2247133.

Purdue MP, Hoppin JA, Blair A, Dosemeci M, and Alavanja MC. 2007. Occupational exposure to organochlorine insecticides and cancer incidence in the Agricultural Health Study. Int J Cancer, 120(3), 642-649. PMCID: PMC1971137.

Raaschou-Nielsen O, Ketzel M, Harbo Poulsen A, and Sorensen M. 2016. Traffic-related air pollution and risk for leukaemia of an adult population. Int J Cancer, 138(5), 1111-1117. PMID: 26415047.

Rauscher GH, Shore D, and Sandler DP. 2004. Alcohol intake and incidence of de novo adult acute leukemia. Leuk Res, 28(12), 1263-1265. PMID: 15475066.

Rauscher GH, Shore D, and Sandler DP. 2004. Hair dye use and risk of adult acute leukemia. Am J Epidemiol, 160(1), 19-25. PMID: 15229113.

Richardson D, Sugiyama H, Nishi N et al. 2009. Ionizing radiation and leukemia mortality among Japanese Atomic Bomb Survivors, 1950-2000. Radiat Res, 172(3), 368-382. PMID: 19708786.

Richardson DB, Terschuren C, Pohlabeln H, Jockel KH, and Hoffmann W. 2008. Temporal patterns of association between cigarette smoking and leukemia risk. Cancer Causes Control, 19(1), 43-50. PMID: 17906957.

Rinsky RA, Hornung RW, Silver SR, and Tseng CY. 2002. Benzene exposure and hematopoietic mortality: A long-term epidemiologic risk assessment. Am J Ind Med, 42(6), 474-480. PMID: 12439870.

Rivina L, Davoren M, and Schiestl RH. 2014. Radiation-induced myeloid leukemia in murine models. Hum Genomics, 8, 13. PMCID: PMC4128013.

Rollig C, Bornhauser M, Thiede C et al. 2011. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol, 29(20), 2758-2765. PMID: 21632498.

Rommens J, and Durie P. 2008. Shwachman-Diamond syndrome. In: Pagon R, Bird T, Dolan C, and Stephens K (Eds.), GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle.

Rosenbaum T, and Wimmer K. 2014. Neurofibromatosis type 1 (NF1) and associated tumors. Klin Padiatr, 226(6-7), 309-315. PMID: 25062113.

Ross JA, Blair CK, Cerhan JR et al. 2011. Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia. Cancer Epidemiol Biomarkers Prev, 20(8), 1741-1750. PMCID: PMC3153558.

Ruhl J, Adamo M, and Dickie L. 2015. Hematopoietic and Lymphoid Neoplasm Coding Manual. Bethesda: National Cancer Institute.

Rushton L, Schnatter AR, Tang G, and Glass DC. 2014. Acute myeloid and chronic lymphoid leukaemias and exposure to low-level benzene among petroleum workers. Br J Cancer, 110(3), 783-787. PMCID: PMC3915135.

Sakata R, Kleinerman RA, Mabuchi K et al. 2012. Cancer mortality following radiotherapy for benign gynecologic disorders. Radiat Res, 178(4), 266-279. PMCID: PMC3471655.

Saliba J, Saint-Martin C, Di Stefano A et al. 2015. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat Genet, 47(10), 1131-1140. PMID: 26280900.

Sant M, Allemani C, Tereanu C et al. 2010. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood, 116(19), 3724-3734. PMID: 20664057.

Saso R, Kulkarni S, Mitchell P et al. 2000. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer, 83(1), 91-94. PMCID: PMC2374543.

Savage SA, Giri N, Baerlocher GM et al. 2008. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet, 82(2), 501-509. PMCID: PMC2427222.

SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). 2015. Potential health effects of exposure to electromagnetic fields (EMF): http://ec.europa.eu/health/scientific\_committees/emerging/docs/scenihr\_o\_041.pdf

Schlenk RF, Dohner K, Krauter J et al. 2008. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med, 358(18), 1909-1918. PMID: 18450602.

Schnatter AR, Glass DC, Tang G, Irons RD, and Rushton L. 2012. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst, 104(22), 1724-1737. PMCID: PMC3502195.

Schwilk E, Zhang L, Smith MT, Smith AH, and Steinmaus C. 2010. Formaldehyde and leukemia: an updated meta-analysis and evaluation of bias. J Occup Environ Med, 52(9), 878-886. PMID: 20798648.

SEER. 2015. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2014 Sub (1973-2012) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission.

SEER. 2015. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\*Stat Database: Incidence - SEER 13 Regs Research Data, Nov 2014 Sub (1992-2012) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission.

SEER. 2015. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (2000-2012) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission.

Seminog OO, and Goldacre MJ. 2013. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br J Cancer, 108(1), 193-198. PMCID: PMC3553528.

Severson RK, Davis S, Thomas DB et al. 1989. Acute myelocytic leukemia and prior allergies. J Clin Epidemiol, 42(10), 995-1001. PMID: 2809658.

Severson RK, Stevens RG, Kaune WT et al. 1988. Acute nonlymphocytic leukemia and residential exposure to power frequency magnetic fields. Am J Epidemiol, 128(1), 10-20. PMID: 3381818.

Shadman M, White E, De Roos AJ, and Walter RB. 2013. Associations between allergies and risk of hematologic malignancies: results from the VITamins and lifestyle cohort study. Am J Hematol, 88(12), 1050-1054. PMCID: PMC4001851.

Shiels MS, and Engels EA. 2012. Increased risk of histologically defined cancer subtypes in human immunodeficiency virus-infected individuals: clues for possible immunosuppression-related or infectious etiology. Cancer, 118(19), 4869-4876. PMCID: PMC3366173.

Shilnikova NS, Preston DL, Ron E et al. 2003. Cancer mortality risk among workers at the Mayak nuclear complex. Radiat Res, 159(6), 787-798. PMID: 12751962.

Shimizu Y, Pierce DA, Preston DL, and Mabuchi K. 1999. Studies of the mortality of atomic bomb survivors. Report 12, part II. Noncancer mortality: 1950-1990. Radiat Res, 152(4), 374-389. PMID: 10477914.

Shizuru JA, Negrin RS, and Weissman IL. 2005. Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med, 56, 509-538. PMID: 15660525.

Shlush LI, and Minden MD. 2015. Preleukemia: the normal side of cancer. Curr Opin Hematol, 22(2), 77-84. PMID: 25575035.

Shore RE, Moseson M, Harley N, and Pasternack BS. 2003. Tumors and other diseases following childhood x-ray treatment for ringworm of the scalp (Tinea capitis). Health Phys, 85(4), 404-408. PMID: 13678280.

Shu XO, Gao YT, Linet MS et al. 1987. Chloramphenicol use and childhood leukaemia in Shanghai. Lancet, 2(8565), 934-937. PMID: 2889862.

Siegel RL, Miller KD, and Jemal A. 2016. Cancer statistics, 2016. CA Cancer J Clin, 66(1), 7-30. PMID: 26742998.

Sielken RL, Jr., and Valdez-Flores C. 2015. A comprehensive review of occupational and general population cancer risk: 1,3-Butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm. Chem Biol Interact, 241, 50-58. PMID: 26070419.

Simon SL, Preston DL, Linet MS et al. 2014. Radiation organ doses received in a nationwide cohort of U.S. radiologic technologists: methods and findings. Radiat Res, 182(5), 507-528. PMCID: PMC4406479.

Sinner PJ, Cerhan JR, Folsom AR, and Ross JA. 2005. Positive association of farm or rural residence with acute myeloid leukemia incidence in a cohort of older women. Cancer Epidemiol Biomarkers Prev, 14(10), 2446-2448. PMID: 16214930.

Smith A, Howell D, Patmore R, Jack A, and Roman E. 2011. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer, 105(11), 1684-1692. PMCID: 3242607.

Smith A, Roman E, Howell D et al. 2009. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol, 148(5), 739-753. PMCID: 3066245.

Smith AG, Dovey GJ, and Cartwright RA. 2000. Topical chloramphenicol and the risk of acute leukaemia in adults. Pharmacoepidemiol Drug Saf, 9(3), 215-219. PMID: 19025822.

Smith ML, Cavenagh JD, Lister TA, and Fitzgibbon J. 2004. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med, 351(23), 2403-2407. PMID: 15575056.

Soderberg KC, Hagmar L, Schwartzbaum J, and Feychting M. 2004. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health, 4, 51. PMCID: PMC534807.

Sokal JE, Cox EB, Baccarani M et al. 1984. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood, 63(4), 789-799. PMID: 6584184.

Song WJ, Sullivan MG, Legare RD et al. 1999. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet, 23(2), 166-175. PMID: 10508512.

Srour SA, Devesa SS, Morton LM et al. 2016. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-2012. Britsh Journal of Haematology, 172(?).

Stebbings JH. 1998. Dose-response analyses of osteonecrosis in New Jersey radium workers point to roles for other alpha emitters. Health Phys, 74(5), 602-607. PMID: 9570164.

Stevens W, Thomas DC, Lyon JL et al. 1990. Leukemia in Utah and radioactive fallout from the Nevada test site. A case-control study. JAMA, 264(5), 585-591. PMID: 2366297.

Storm HH, Jorgensen HO, Kejs AM, and Engholm G. 2006. Depleted uranium and cancer in Danish Balkan veterans deployed 1992-2001. Eur J Cancer, 42(14), 2355-2358. PMID: 16857358.

Strom SS, Yamamura Y, Kantarijian HM, and Cortes-Franco JE. 2009. Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev, 18(5), 1501-1506. PMCID: PMC2918285.

Strullu M, Caye A, Lachenaud J et al. 2014. Juvenile myelomonocytic leukaemia and Noonan syndrome. J Med Genet, 51(10), 689-697. PMID: 25097206.

Swerdlow SH, Campo E, Harris NL et al (Eds.). 2008. WHO classification of tumours of haematopoietic and lymphoid tissues (4 ed.). Lyon: International Agency for Research on Cancer.

Talbott EO, Xu X, Youk AO et al. 2011. Risk of leukemia as a result of community exposure to gasoline vapors: a follow-up study. Environ Res, 111(4), 597-602. PMID: 21453914.

Tapper W, Jones AV, Kralovics R et al. 2015. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun, 6, 6691. PMCID: PMC4396373.

Tefferi A, and Pardanani A. 2015. Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol, 1(1), 97-105. PMID: 26182311.

Thariat J, Marcy PY, Lacout A et al. 2012. Radiotherapy and radiology: joint efforts for modern radiation planning and practice. Diagn Interv Imaging, 93(5), 342-350. PMID: 22483122.

Thygesen LC, Nielsen OJ, and Johansen C. 2009. Trends in adult leukemia incidence and survival in Denmark, 1943-2003. Cancer Causes Control, 20(9), 1671-1680. PMID: 19672681.

Till JE, Beck HL, Aanenson JW et al. 2014. Military participants at U.S. Atmospheric nuclear weapons testing--methodology for estimating dose and uncertainty. Radiat Res, 181(5), 471-484. PMCID: PMC4082990.

Tomasek L, Darby SC, Swerdlow AJ, Placek V, and Kunz E. 1993. Radon exposure and cancers other than lung cancer among uranium miners in West Bohemia. Lancet, 341(8850), 919-923. PMID: 8096265.

Tong H, Hu C, Yin X et al. 2013. A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes. PLoS One, 8(6), e67537. PMCID: PMC3689714.

Traversa G, Menniti-Ippolito F, Da Cas R et al. 1998. Drug use and acute leukemia. Pharmacoepidemiol Drug Saf, 7(2), 113-123. PMID: 15073735.

Travis LB, Hauptmann M, Gaul LK et al. 2003. Site-specific cancer incidence and mortality after cerebral angiography with radioactive thorotrast. Radiat Res, 160(6), 691-706. PMID: 14640794.

Travis LB, Holowaty EJ, Bergfeldt K et al. 1999. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med, 340(5), 351-357. PMID: 9929525.

Tucker JD. 2010. Chromosome translocations and assessing human exposure to adverse environmental agents. Environ Mol Mutagen, 51(8-9), 815-824. PMID: 20213842.

Tynes T, and Haldorsen T. 2003. Residential and occupational exposure to 50 Hz magnetic fields and hematological cancers in Norway. Cancer Causes Control, 14(8), 715-720. PMID: 14674735.

Udayakumar AM, Surekhatony M, and Wali YA. 2014. Myelodysplasia progressing to acute myeloid leukemia in monozygotic twins with monosomy 7 as sole abnormality. Leuk Lymphoma, 55(11), 2672-2674. PMID: 24598016.

Vardiman JW, Harris NL, and Brunning RD. 2002. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100(7), 2292-2302. PMID: 12239137.

Vardiman JW, Thiele J, Arber DA et al. 2009. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114(5), 937-951. PMID: 19357394.

Varley J, Evans D, and Birch J. 1997. Li-Fraumeni syndrome--a molecular and clinical review. British Journal of Cancer, 76(1), 1-14.

Verkasalo PK, Pukkala E, Kaprio J, Heikkila KV, and Koskenvuo M. 1996. Magnetic fields of high voltage power lines and risk of cancer in Finnish adults: nationwide cohort study. BMJ, 313(7064), 1047-1051. PMCID: PMC2352388.

Vijayakrishnan J, and Houlston R. 2010. Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: A systematic review and meta-analysis. Haematologica, 95(8), 1405-1414. PMID: 20511665.

Visser O, Trama A, Maynadie M et al. 2012. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer, 48, 2357-66. PMID 22720878

Vlaanderen J, Lan Q, Kromhout H, Rothman N, and Vermeulen R. 2012. Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. Am J Ind Med, 55(9), 779-785. PMID: 22729623.

Voso MT, Fenu S, Latagliata R et al. 2013. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol, 31(21), 2671-2677. PMID: 23796988.

Wakeford R. 2009. Radiation in the workplace-a review of studies of the risks of occupational exposure to ionising radiation. J Radiol Prot, 29(2A), A61-79. PMID: 19454806.

Wang P, Liu H, Jiang T, and Yang J. 2015. Cigarette Smoking and the Risk of Adult Myeloid Disease: A Meta-Analysis. PLoS One, 10(9), e0137300. PMCID: PMC4560392.

Wei L, and Sugahara T. 2000. An introductory overview of the epidemiological study on the population at the high background radiation areas in Yangjiang, China. J Radiat Res, 41 Suppl, 1-7. PMID: 11142208.

Weiss HA, Darby SC, Fearn T, and Doll R. 1995. Leukemia mortality after X-ray treatment for ankylosing spondylitis. Radiat Res, 142(1), 1-11. PMID: 7899552.

Weiss JR, Baker JA, Baer MR et al. 2006. Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia. Leuk Res, 30(2), 164-169. PMID: 16099041.

Wheatley K, Brookes CL, Howman AJ et al. 2009. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol, 145(5), 598-605. PMID: 19344426.

Wick RR, Nekolla EA, Gaubitz M, and Schulte TL. 2008. Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224. Rheumatology (Oxford), 47(6), 855-859. PMID: 18390588.

Wilkinson P, Thakrar B, Walls P et al. 1999. Lymphohaematopoietic malignancy around all industrial complexes that include major oil refineries in Great Britain. Occup Environ Med, 56(9), 577-580. PMCID: PMC1757785.

Williams RR, and Horm JW. 1977. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. J Natl Cancer Inst, 58(3), 525-547. PMID: 557114.

Wong O, Harris F, Yiying W, and Hua F. 2009. A hospital-based case-control study of acute myeloid leukemia in Shanghai: analysis of personal characteristics, lifestyle and environmental risk factors by subtypes of the WHO classification. Regul Toxicol Pharmacol, 55(3), 340-352. PMID: 19703505.

Wright JD, St Clair CM, Deutsch I et al. 2010. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer, 116(10), 2486-2492. PMID: 20209618.

Xavier AC, and Taub JW. 2010. Acute leukemia in children with Down syndrome. Haematologica, 95(7), 1043-1045.

Yamamura Y, Oum R, Gbito KY, Garcia-Manero G, and Strom SS. 2013. Dietary intake of vegetables, fruits, and meats/beans as potential risk factors of acute myeloid leukemia: a Texas case-control study. Nutr Cancer, 65(8), 1132-1140. PMID: 24168094.

Yenson PR, Forrest D, Schmiegelow K, and Dalal BI. 2008. Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency. Am J Hematol, 83(1), 80-83. PMID: 17696202.

Yoshinaga S, Mabuchi K, Sigurdson AJ, Doody MM, and Ron E. 2004. Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies. Radiology, 233(2), 313-321. PMID: 15375227.

Zablotska LB, Bazyka D, Lubin JH et al. 2013. Radiation and the risk of chronic lymphocytic and other leukemias among chornobyl cleanup workers. Environ Health Perspect, 121(1), 59-65. PMCID: PMC3553431.

Zablotska LB, Lane RS, Frost SE, and Thompson PA. 2014. Leukemia, lymphoma and multiple myeloma mortality (1950-1999) and incidence (1969-1999) in the Eldorado uranium workers cohort. Environ Res, 130, 43-50. PMCID: PMC4002578.

Zeichner SB, and Arellano ML. 2015. Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process. Curr Treat Options Oncol, 16(8), 37. PMID: 26143266.

Zhang L, Tang X, Rothman N et al. 2010. Occupational exposure to formaldehyde, hematotoxicity, and leukemia-specific chromosome changes in cultured myeloid progenitor cells. Cancer Epidemiol Biomarkers Prev, 19(1), 80-88. PMCID: PMC2974570.

Zhang Y, Kim C, and Zheng T. 2012. Hair dye use and risk of human cancer. Front Biosci (Elite Ed), 4, 516-528. PMID: 22201892.

Zheng W, Linet MS, Shu XO et al. 1993. Prior medical conditions and the risk of adult leukemia in Shanghai, People's Republic of China. Cancer Causes Control, 4(4), 361-368. PMID: 8347786.

Zhou J, Eksioglu EA, Fortenbery NR et al. 2011. Bone marrow mononuclear cells up-regulate toll-like receptor expression and produce inflammatory mediators in response to cigarette smoke extract. PLoS One, 6(6), e21173. PMCID: PMC312.